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ABSTRACT
The ketogenic diet has grown in popularity in the last decade as a weight loss tool.
Research into the diet’s effects on the body have revealed a variety of other health benefits. The
use of exogenous ketone supplements to confer the benefits of the diet without strict adherence
to it represents an exciting new area of focus. Synthetic ketogenic compounds are of particular
interest that has received very little emphasis and is an untapped area of focus for chemical
synthesis.
The first chapter of this manuscript provides an overview of the history of the ketogenic
diet along with a summary of the benefits and limitations of the diet, and the biochemistry
behind it. It provides a summary of the current research surrounding synthetic ketogenic
compounds and justifies the synthesis of novel synthetic ketogenic compounds.
The second chapter discusses the synthesis of a series of compounds designed with the
goal of generating an increase to ketone body levels in the body. The third and fourth chapter
discuss in vivo and in vitro testing done on these compounds to justify their use as novel
synthetic ketogenic compounds and to justify further research into the field.

xv

CHAPTER I

THE CHEMISTRY OF THE KETOGENIC DIET: UPDATES AND
OPPORTUNITIES IN ORGANIC SYNTHESIS

1.1 Introduction
The ketogenic diet, a high-fat, low-carbohydrate diet, has a long history of use beginning
primarily as a treatment option for epilepsy.1-2 However, it is only in the last few decades that
the diet has been popularized among the general public. Renewed clinical interest in the diet and
its emerging popularity as a weight-loss tool have led to a larger scope of research into the diet’s
effects on the body, and to the discovery of a broad range of physical, biochemical, and cosmetic
benefits.
Even with expanding research interest in the ketogenic diet, most prior reported studies
have been done in clinical settings or in biology labs.3-4 Emerging research shows that certain
ketogenic supplements can confer some of the benefits of the ketogenic diet while following a
normal diet.5-6 Difficulty in adherence to the ketogenic diet is often cited as a reason why it is
abandoned due to limited food options. If these obstacles can be overcome, a wide array of
possibilities may open up. Yet, very little work has been done so far in expanding the options to
do this, particularly from the chemistry side. This review will cover the history and health-related
aspects of the ketogenic diet and its biochemical basis as well as highlight some exciting
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opportunities in organic synthesis to devise routes to potential new ketogenic compounds as
components or supplements of the ketogenic diet.

1.2 History of the Ketogenic Diet
Dietary fasting has been a common societal practice in various religions for thousands of
years, and as a treatment for epilepsy for over a century. Much of the early reported information
is based on the personal experience of cultists and physicians instead of scientifically-motivated
clinical trials. In 1911, two French physicians Guelpa and Marie published a report detailing
their use of fasting to treat epileptic seizures, in which six of their 26 patients showed a reduction
in the severity of their seizures or the rate of seizure occurrence.7 No further details were
provided. At the American Medical Association convention in 1921, Geyelin presented a report
of a controlled study involving 36 epileptic patients who used fasting as a treatment plan.8 The
results showed that 80% of these patients experienced a decrease in the number of seizures.
Despite this promising outcome, fasting saw sporadic use among physicians to try to control
epileptic seizures, but no formal clinical trials were done and its use as a long-term treatment
method was obviously not viable.
Around the same time, research into the use of diet modification to control diabetes
mellitus was developing. The difference between type I and type II diabetes was not understood
at that time and so there was no distinction made. Newburgh and Marsh reported the use of a
high-fat, low-carbohydrate diet to manage diabetes in 1920.9-11 In 1921, Woodyatt published a
review article on the modification of diet to control diabetes mellitus based on his own research
and that of Philip Shaffer, who sought to study the relationship between acetoacetic acid and
glucose in vitro.12-13 It had long been known that diabetic patients often had an increased

2

concentration of acetoacetic acid, (R)-b-hydroxybutyric acid, and acetone in their blood
(ketonemia) and urine (ketourea) based on research done by Gerhardt in 1865.14 These three
compounds are collectively known as the ketone bodies (Fig. 1.1).

Figure 1.1: The Ketone Bodies

This increase in blood concentrations of the ketone bodies had been shown by
Geelmudyen in 1897 to be caused by an increase in the metabolism of fatty acids, due to diabetic
patients’ inability to metabolize glucose at a rate fast enough to meet caloric needs.15 This can be
dangerous for those with diabetes because unchecked ketonemia can lead to a state we now
know as diabetic ketoacidosis, where excess ketone bodies acidify the blood, leading to nausea,
weakness, and even death. Woodyatt suggested a diet based on Newburgh and Marsh’s research
where the amount of carbohydrates consumed did not exceed the quantity the body could
metabolize, and to supplement the diet with fats. This prevented the buildup of sugar in the
blood (hyperglycemia), one of the causes of ketonemia. Woodyatt believed that over time,
resting the pancreas would increase the body’s capability to metabolize carbohydrates and a
normal diet could be resumed. The discovery of insulin in 1921 and its use to treat diabetes
mellitus starting in 1922 decreased the need for other treatment options, but the interest in highfat, low-carbohydrate diets continued to grow.16
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Later that same year, Wilder published a report based on Geyelin’s use of fasting as a
treatment for epilepsy and suggested that it may be due to the patients’ ketonemia.17 Referencing
Shaffer’s work, Wilder suggested inducing ketonemia not through fasting, but through a high-fat,
low-carbohydrate diet he referred to as the ‘ketogenic diet’. Peterman, one of his colleagues,
formulated the optimized amounts of macronutrients for the diet, as being no more than 15 grams
of carbohydrates a day, 1 gram of protein per kilogram of body weight, and the remaining caloric
deficit made up of fats. This is nearly identical to the modern ketogenic diet, a 4:1 ratio of fats to
carbohydrates and protein with a maximum allowance of 50 grams of carbohydrates per day.
Wilder released a report shortly after this on three of his patients who saw a sharp decrease in the
rate of seizures.18
Further studies over the next few years corroborated the use of the ketogenic diet as a
treatment for epilepsy.19 Peterman reported his own observations in 1924 across two studies on
the use of the ketogenic diet compared to a variety of other treatments. In the first, nine out of 13
patients using only the ketogenic diet as treatment for their epilepsy were free of seizures for up
to a year.1 In the second study, 19 out of 37 were seizure-free for up to two years.20 In 1927,
Talbot reported a study of 200 children where the ketogenic diet provided complete symptomatic
relief among a third and partial improvement to three quarters.21 Helmholz reported the use of
the diet across 144 epileptic patients. Forty-six patients were seizure-free, and 34 saw a decrease
in the rates of seizure occurrence.22
The use of medication to treat epilepsy was gaining popularity around this time as well
(Fig. 1.2). Phenobarbital was brought to market as an anti-convulsant in 1912 and was one of the
treatment options Peterman compared to the ketogenic diet.1,23 Phenytoin was synthesized in
1908 and shown to be useful for preventing seizures in 1936.24 Carbamazepine and sodium
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valproate were both brought to market in 1962.25-26 All are still used and are currently on the
World Health Organization Model List of Essential Medicines. The emergence of novel
anticonvulsant medications caused the ketogenic diet to decrease in popularity as a treatment
option, possibly because it was thought that medicinal options would eliminate behavioral
changes altogether.27 Nonetheless, the ketogenic diet never completely disappeared. The
difficulty in developing a widely-accepted medicinal treatment protocol to control epileptic
seizures led to its sporadic use.

Figure 1.2: Common Anticonvulsant Medications

Johns Hopkins Hospital in particular seemed to use the diet for epilepsy treatment more
often than most health care centers, publishing reviews and reports on its efficacy in the 1980’s
and 1990’s.27-29 The cause of the diet’s subsequent upswing in popularity is at least partially due
to the efforts of Jim Abrahams, a film director whose son Charlie’s seizures were treated
successfully at Johns Hopkins using the ketogenic diet. His son’s story was documented on
Dateline NBC in 1994 and he started a foundation called the Charlie Foundation to spread
awareness and fund research into the ketogenic diet.30 It is likely because of this increase in
publicity that popularity and interest in the diet grew, leading to a surge of research in the past
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twenty five years.31 The research has helped to expand the benefits of the ketogenic diet beyond
its use as a treatment for epilepsy.32
While early use of the ketogenic diet to treat epilepsy was done without a full
understanding of the biochemistry through which ketone bodies are generated and utilized,
research over the past century has further elucidated these pathways.

1.3 Competing Energy Sources in the Body
Energy for the body comes from the digestion and metabolic breakdown of
macronutrients (fats, carbohydrates, and protein) in the diet. The body prioritizes carbohydrate
metabolism due to their availability from the diet and from stored glycogen in the liver and in
muscles, chemically converting them through hydrolysis to glucose, which is oxidatively broken
down through glycolysis to S-acetyl coenzyme A (or S-acetyl CoA). S-Acetyl CoA is needed to
fuel the Krebs cycle, which completes the conversion of upstream carbon sources to carbon
dioxide and adenosine triphosphate (ATP), the primary source of energy in cells (Fig. 1.3).

Figure 1.3: Adenosine Triphosphate (ATP)

Fats can likewise be broken down hydrolytically to fatty acids that metabolically produce
S-acetyl CoA for the Krebs cycle. This occurs through a repetitive b-oxidation process in the
mitochondrion of liver cells (mostly). Normally, these two pathways to S-acetyl CoA are
6

complementary and carefully regulated metabolically. However, when pushed beyond this
regulation by dietary consumption or by the body´s immediate energy needs, the pathways can
become competitive. Indeed, by limiting the availability of carbohydrates in the diet and the
accumulation of stored glucose (glycogen reserves), the body can switch to the use of dietary or
stored fats to produce the S-acetyl CoA needed for the Krebs cycle (Fig. 1.4).

Figure 1.4: Metabolic Sources of S-Acetyl CoA

1.4 Dietary Fats
While the ratio of macronutrients in the ketogenic diet has remained relatively unchanged
since its development in 1921, there is some variety within the dietary fats we consume. Fats are
lipophilic, largely water-insoluble substances that can be extracted from living cells with
common organic solvents such as hexane or diethyl ether, and depending on their structures, can
appear as oils, semi-solids, or greasy waxes at room temperature. Collectively, these organicsoluble compounds can be referred to commonly as lipids and include a wide range of structural
types that include long chain ester derivatives such as triacylglycerides, branched chain
compounds comprised of a wide assortment of terpenes and terpenoids such as the steroids (e.g.
cholesterol) and their fatty esters. Figure 1.5 illustrates some examples of common dietary lipids.
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Figure 1.5: Examples of Common Dietary Fats

Dietary fats are primarily triacylglycerides (triglycerides), a glycerol backbone bound to
three carboxylic acids with long aliphatic chains (fatty acids) via ester bonds.
Monoacylglycerides and diacylglycerides are also naturally occurring, but not as abundant in the
diet (Fig. 1.6).

Figure 1.6: Dietary Acylglyceride Fats
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The triglycerides found in the diet are composed of three long-chain fatty acids (between
14 and 22 carbons), and may be identical or different in the carbon chain length or in the
presence of unsaturation or oxygenation in the chain.33 The number of alkenes in the chain can
vary as well, from being monounsaturated, or polyunsaturated (Fig. 1.6). The alkene geometry
can likewise be either E or Z, although nearly all examples in nature are Z. The length of the
carbon chain, and the location or the type of alkene(s) within the fatty ester chain, largely
determine the physical and to some extent the biochemical properties of the triglyceride, with
fully saturated chains or those having E-alkenes being more conformationally-rigid and leading
to compounds with higher melting points. Plants and animals that live in cold environments
produce a greater abundance of triglycerides and other fatty lipids that remain fluid at low
temperatures, depending on the required function and physical state.
The fatty acid concentrations in triacylglycerides also vary greatly based on the source of
fat. The concentrations of specific fatty acids in different sources of fat can be analyzed by
cleaving the fatty acids from triacylglycerides and converting them into their ester forms. Using
these methods, the primary fatty acids in different fats have been studied (Fig. 1.7).33-34 These
concentrations can also be affected by environmental factors within specific dietary fat sources.35
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Figure 1.7: Major Fatty Acids in Common Foods

The long alkyl chains found in most dietary fats are useful biofuels for cells, as their
carbons are in a higher reduction state (typically -2 or -3) than those in carbohydrates (around 0).
Consequently, fats store about double the potential energy within their structures, which is
released when converted in cells to CO2.

1.5 Biochemistry of the Ketogenic Diet
The biochemistry behind the ketogenic diet is relatively simple. The ketogenic diet
attempts to emulate the body’s response to starvation or fasting by eliminating carbohydrates as
the provider of S-acetyl CoA, and thus the body´s source of energy. When carbohydrates are
unrestricted in the diet, the glucose present in cells or in the blood is enzymatically converted to
pyruvate through the glycolytic pathway (Fig. 1.8).
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Figure 1.8: Metabolism of Glucose

The glycolysis pathway generates energy in the form of adenosine triphosphate (ATP).
The pyruvate is then converted to S-acetyl CoA to be used as fuel for the Krebs cycle, the body’s
primary chemical process for generating ATP (and its direct link to the mitochondrial electrontransport chain).
When carbohydrates are abundantly available in the food we eat, the increase in blood
glucose concentration signals the pancreas to secrete insulin, a protein hormone that stimulates
the cellular absorption of glucose from the blood. Insulin-dependent glucose uptake is largely
responsible for excess glucose to be stored in the liver and skeletal muscle as glycogen, and for
the conversion of glucose (along with glycerol from the hydrolysis of triglycerides) to be used in
the biosynthesis of triacyglycerides that end up being stored in adipose tissue.36 As a result of
these processes, the blood glucose concentration is maintained at a steady state of around 80-120
mg/dL of blood, and upon the burning of glucose through the Krebs cycle, ultimately decreases
to a point where glucagon (another protein hormone) is released by the pancreas to orchestrate
the break-down of stored glycogen to release more glucose into the blood. These glycogen
stores typically last for about a day. When more carbohydrates are consumed, more insulin is
released to accelerate the uptake of glucose to replenish glycogen stores, and the process repeats
itself.37 An average 180-pound man typically stores around one pound of glycogen in the liver
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(giving about a day’s worth of energy) but around 40 times that amount in fat deposited inside of
adipocytes (fat cells).
However, if glycogen stores are depleted and no carbohydrates are consumed, the body
will begin to break down both dietary triacylglycerides and triacylglycerides contained in
adipose cells through the process of lipolysis (Fig. 1.9).38 The first step in lipolysis is the
removal of the first fatty acid, in this case stearic acid, from the triglyceride. It requires a unique
lipase called adipose triglyceride lipase. Adipose triglyceride lipase shows a preference for
hydrolyzing the middle ester of triacylglycerides.39 Similarly, hormone-sensitive lipase
hydrolyzes diacyglycerol with a preference for 1,3-diacylglycerols. Monoacylglycerol lipase
hydrolyzes the final fatty acid to generate glycerol and a net total of three fatty acids. These
enzymes are relatively nonspecific because of the large variety of unique triacylglcerides in the
diet.

Figure 1.9: Lipolysis of Triacylglycerides
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Dietary fats are broken down in a similar manner. Lingual lipases secreted in the mouth
and gastric lipases in the stomach break down some triacylglycerides into mono- and
diacylglycerides. Bile salts in the small intestine emulsify fats and allow pancreatic lipases to
cleave triacylglycerides that are not cleaved in the mouth or stomach. Free fatty acids and the
mono- and diacyglycerides are then absorbed by intestinal mucosal cells and combined to form
triacylglycerides that can be dissolved in lipoprotein complexes called chylomicrons.
Chylomicrons are able to carry insoluble fats through the bloodstream. They are absorbed by
liver, adipose, and muscle cells where the triacylglycerides are hydrolyzed by lipoprotein and
hepatic triglyceride lipases to generate free fatty acids.
The fatty acids released either through lipolysis or through the digestion of dietary fats
are carried through the blood by albumin until they are absorbed by cells and used as an energy
source. The glycerol released by the breakdown of triacylglcyerides can be used to synthesize
new triacylglycerides or can be converted in the liver to glyceraldehyde-3-phosphate and enter
the gluconeogenesis pathway to generate glucose, but this will not meet the caloric requirements
of the body (Fig. 1.10).
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Figure 1.10: Metabolic Conversion of Glycerol to Glucose

Instead, the fatty acids released by lipolysis are absorbed by the cells and converted into
S-acetyl CoA through b-oxidation. This process is a repeating set of steps that converts the bcarbon of the fatty acid into a carbonyl group and then cleaves off an S-acetyl CoA, shortening
the fatty acid (Fig. 1.11).
The first step in fatty acid b-oxidation is the thioesterification by coenzyme A, which
assists in transport to the mitochondrial outer membrane. Inside the mitochondrion, the first step
is a regioselective dehydrogenation reaction. Next, the alkene is hydrated to generate a hydroxyl
group at the b-carbon. This addition is stereoselective for the S-enantiomer. The penultimate
step is the NAD+ oxidation of the secondary alcohol to a ketone. Finally, S-acetyl CoA is
cleaved and the resulting fatty acid chain is two carbon atoms shorter. The cycle repeats itself
until the fatty acid is fully converted to S-acetyl CoA with some minor differences for
unsaturated fatty acids and those with odd-numbered carbon chain lengths.
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Figure 1.11: b-Oxidation of a Fatty Acid

The S-acetyl CoA generated by cells through b-oxidation can directly enter the Krebs
cycle and provide energy in the form of ATP. For most of the cells in the body, this process
could supply their energy needs until all triglycerides are depleted. However, because fatty acids
cannot cross the blood-brain barrier, they cannot be absorbed and used by cells in the brain. The
brain uses approximately 20% of the energy our body requires, which necessitates an effective
method for providing lasting energy when carbohydrate consumption is low.3,40
The body overcomes this obstacle by converting S-acetyl CoA into the three ketone
bodies (Fig. 1), water-soluble compounds that can enter the blood, cross the blood-brain barrier,
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and be absorbed by neuronal cells in the brain before being converted to S-acetyl CoA to fuel the
Krebs cycle. While they are presented here in their acid forms, these two acids are deprotonated
at physiological pH and referred to as acetoacetate and (R)-b-hydroxybutyrate.41
The metabolic process of generating ketone bodies from S-acetyl CoA occurs through
ketogenesis, and takes place primarily in the liver (Fig. 1.12).

Figure 1.12: Ketogenesis of Ketone Bodies from S-Acetyl CoA
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The first step is the Claisen-type condensation of two molecules of S-acetyl CoA to form
S-acetoacetyl CoA. This is followed by an aldol addition of another S-acetyl CoA to the bcarbonyl with subsequent hydrolysis of one of the coenzyme A thioesters to generate a
carboxylic acid. The S-acetyl CoA is cleaved by HMG-CoA lyase to generate acetoacetic acid
which can subsequently be reduced by 3-hydroxybutyrate dehydrogenase to generate (R)-bhydroxybutyric acid. Decarboxylation of acetoacetic acid, which can subsequently generate
acetone and carbon dioxide, can occur spontaneously as well, although this is primarily the
method through which excess ketone bodies are removed as waste.
While S-acetoacetyl CoA could be hydrolyzed to generate acetoacetic acid directly, there
is evidence that the expression of HMG-CoA synthase plays a role in limiting the rate at which
ketogenesis occurs.42 The ketone bodies generated in the liver are released into the blood where
they can be absorbed by other cells and used to generate S-acetyl CoA through the process of
ketolysis (Fig. 1.13).

Figure 1.13: Ketolysis of the Ketone Bodies
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First, NAD+ oxidation converts (R)-b-hydroxybutyric acid to acetoacetic acid, which
undergoes trans-thioesterification with S-succinyl CoA to generate S-acetoacetyl CoA. SAcetoacetyl CoA is cleaved by coenzyme A through a retro-Claisen reaction to generate two Sacetyl CoA molecules that can directly enter the Krebs cycle. Although it is a ketone body,
acetone does not play a role in ketolysis and is instead excreted in the urine and through the
lungs.

1.5.1 Metabolic Effect of Ketolysis Versus Glycolysis
Limiting the body’s use of traditional pathways of generating energy through glycolysis
in favor of using ketone bodies has a profound effect on the body. While the complete
mechanism is not fully understood, bypassing carbohydrate metabolism in the brain can lead to a
decreased incidence or even the elimination of epileptic seizures.6
The state of having elevated ketone bodies in the blood is called ketosis. Typical ketone
body concentrations during dietary ketosis are between 0.5-3 mM, while a normal diet will give
ketone body concentrations of less than 0.3 mM.43 Achieving and keeping the body in a state of
ketosis is the goal of the ketogenic diet, as any carbohydrates above an absolute bare minimum
will trigger the release of insulin and rapidly decrease the rate of generation of ketone bodies.
It is important to note that this is different than diabetic ketoacidosis, a potentially lifethreatening condition that occurs primarily in type I diabetics where unchecked ketogenesis can
cause ketone body concentrations to rise to 10mM and beyond, overwhelming the body’s acidbase buffering system and causing the blood to turn acidic.44 Insulin acts as an inhibitor for
lipolysis, b-oxidation, and ketogenesis and prevents the build-up of ketone bodies to unsafe
levels during dietary ketosis.43 Even for those with type II diabetes where insulin sensitivity in
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the cells is decreased, diabetic ketoacidosis is rare since these catabolic processes are very
sensitive to insulin. However, type I diabetics are at risk for diabetic ketoacidosis since the
hormone to stop the generation of ketone bodies is present in low amounts or absent entirely.

1.6 Benefits of the Ketogenic Diet
The use of the ketogenic diet as a treatment option for epilepsy is well-studied, but
research has shown that there are other benefits. The most popular is its efficacy as a weight-loss
tool. Statistical analysis of fourteen studies comparing weight loss using the ketogenic diet or
low-fat diets showed the ketogenic diet caused greater reductions in body weight.45 The diet has
also been shown to be a more effective method for weight loss compared to a normal diet at
similar caloric deficits in trials that range in length from three months to two years.46,47 It is
possible that the initial rapid weight loss when initiating the diet comes from the body’s attempts
to use glycerol from triglycerides to overcome a lack of dietary carbohydrates, leading to a
decrease in adipose fat stores and thus weight. Converting glycerol into glucose through the
gluconeogenesis pathway is also a very energy-demanding process, so the body is using excess
energy before it begins to adapt to using ketone bodies as a primary energy source.
Tangentially related to the benefits of weight loss, the ketogenic diet has been shown to
improve and even reverse insulin resistance in those suffering from type 2 diabetes or for those
who are at risk of becoming diabetic.48,49 Increased insulin resistance has been shown to lead to
higher conversion of glucose into triglycerides that can lead to heart disease.50,51 For obese
patients, the ketogenic diet has been shown to decrease total cholesterol and triglyceride
concentrations in the blood, which can decrease the risk of cardiovascular and metabolic
diseases.52-54
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Alongside the more well-studied benefits of the diet, there is emerging evidence
indicating benefits for other diseases and neurological disorders.55-57 Patients with Parkinson’s
disease have shown improved scores on the Unified Parkinson’s Disease Rating Scale after four
weeks on a ketogenic diet.58 The infusion of (R)-b-hydroxybutyric acid was found to protect
against dopaminergic neurodegeneration induced by neurotoxins that mimic the effects of
Parkinson’s disease and Alzheimer’s disease.59,60 Mouse models have been used to demonstrate
that the ketogenic diet can decrease the concentration of b-amyloid in the brain, a risk factor for
developing Alzheimer’s disease.61 The ketogenic diet has also demonstrated in mice models to
slow the degradation of motor neurons due to amyotrophic lateral sclerosis (ALS).62
It has long been recognized that cancer cells consume glucose at a much higher rate than
normal cells.63,64 Increased glycolysis promotes excessive proliferation in cancer cells.65
However, in vitro studies have shown that a lack of glucose can cause apoptosis in malignant
cells.66-68 Certain tumors are unable to utilize ketone bodies as a source of energy due to a
decrease in ketolysis enzyme activity.69,70 The use of the ketogenic diet to effectively “starve”
certain types of tumors could be an adjuvant treatment alongside more traditional forms of
cancer treatment. In mice, the ketogenic diet has been shown to slow the rate of tumor growth
and improve the effects of radiation treatment.71-73 There are a few published reports of similar
outcomes in human patients, but no formal clinical testing has yet been done.74,75 While much of
this evidence is far from conclusive, it shows the wide range of possibilities the diet holds, which
justifies and indeed creates opportunities for further research.
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1.7 Limitations of the Ketogenic Diet
Most of the long-term effects of the ketogenic diet are based on the children with
epilepsy treated by it. Hyperlipidemia has been seen in a majority of children treated with the
traditional ketogenic diet, although this can be avoided by adjusting the types of fats
consumed.76,77 Kidney stones are seen in approximately 10% of children on the ketogenic
diet.78,79 There is concern that a strict ketogenic diet may affect growth rates, possibly due to
protein or overall calorie restrictions.80,81 There is some evidence that the ketogenic diet can
cause osteopenia, a condition where bone mass is lost, possibly due to vitamin D and calcium
deficiencies.82,83 Those with type I diabetes are at risk for ketoacidosis on the ketogenic diet.
Research into the long-term effects of the ketogenic diet on healthy adults is sparse, but the
recent popularity of the diet makes it likely that these studies will be done.
One of the more common criticisms of the ketogenic diet is that it is difficult to maintain.
Clinical studies from the diet’s earliest use in the 1920’s to treat epilepsy and more recent studies
on weight loss commonly report patients that were unable to follow the diet.20-23,45-47 A single
meal with too high a proportion of carbohydrates will cause the body to fall out of ketosis and
revert back to using carbohydrates as its main energy source.84,85 Long-term adherence to the
diet can be low due to lack of discipline, adverse gastrointestinal effects, or palatability issues.
Modified versions of the ketogenic diet have been developed to address these concerns.
The MCT (medium-chain triglyceride) diet in particular has seen wide use. It focuses on using
naturally-occurring triacylglycerides consisting of medium-chain fatty acids (between 6-12
carbons) that do not require active transport into cells and are instead absorbed by the liver
directly. This increases the rate at which dietary triacylglycerides can be converted to ketone
bodies, but research has also shown that a greater percentage of fatty acids in medium-chain
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triacylglycerides are metabolized in the liver and can be used to generate ketone bodies
compared to longer fatty acids that are partially used in the synthesis of new triacylglycerides to
be stored in adipose tissue.86 Medium-chain triglycerides have been shown to have a greater
effect on ketone body concentration compared to long-chain triglycerides.87 Because of this, the
MCT diet allows for a greater amount of carbohydrates and proteins in the diet and mediumchain triglycerides are considered to be more ‘ketogenic.’ However, it still suffers from many of
the same drawbacks as the traditional ketogenic diet including a reliance on a strict dietary
regiment.
Improving the effectiveness and sustainability of the ketogenic diet using alternative
natural sources of fat does not address many of the primary limiting factors of the diet. The use
of synthetic compounds to induce ketosis could perhaps better address these factors.

1.8 Synthetic Ketogenic Compounds as an Alternative Path to Ketosis
Originally, it was believed that the benefits of the ketogenic diet were due to the decrease
in glucose metabolism. However, more recent studies have shown that some of these benefits
are instead caused by an increase in ketone body concentrations in the blood.88,89 In the past, this
distinction was irrelevant since a normal diet will prevent the body from generating ketone
bodies at a rate high enough to maintain a state of ketosis. However, three synthetic ketogenic
compounds have been shown to increase ketone body concentration in the blood to the point
where dietary ketosis can be maintained without a change from a normal diet (Fig. 1.14).
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Figure 1.14: Synthetic Ketogenic Compounds

(±)-1,3-Butanediol acetoacetate diester was synthesized from (±)-1,3-butanediol and tbutyl acetoacetate via a transesterification reaction, published in 1995 (Fig. 1.15).90

Figure 1.15: Synthesis of (±)-1,3-Butanediol Acetoacetate Diester

This compound is metabolically hydrolyzed to generate two equivalents of acetoacetic
acid and (±)-1,3-butanediol, which can be oxidized to generate b-hydroxybutyric acid (Fig.
1.16).91,92 The oxidation of the (R)-enantiomer occurs in the liver. (S)-b-Hydroxybutyric acid is
not naturally occurring, but its metabolism in perfused rat livers has been shown to generate
ketone bodies through an unknown pathway.93
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Figure 1.16: Oxidation of (R)-b-1,3-Butanediol in the Liver

Racemic 1,3-butanediol acetoacetate diester was shown to increase ketone body
concentrations in the blood of both a pig and dog. More recent studies in rats indicate it induces
a rapid increase in (R)-b-hydroxybutyric acid concentration in the blood and a decrease in blood
glucose concentration, indicative of ketosis.94 Importantly, triglyceride and cholesterol levels did
not change to a statistically relevant level over 28 days of daily administration.6
A similar compound, (R)-3-hydroxybutyl (R)-3-hydroxybutanoate, was synthesized by
Clarke and Veech in 2010.95 A lipase-mediated transesterification reaction between (R)-1,3butanediol and ethyl (R)-3-hydroxybutanoate generates a stereospecific monoester that can be
hydrolyzed to generate (R)-b-hydroxybutyric acid and (R)-1,3-butanediol, which can be oxidized
in the liver to give a second equivalent of (R)-b-hydroxybutyric acid (Fig. 1.17).96

Figure 1.17: Enzymatic Synthesis of (R)-3-hydroxybutyl (R)-3-hydroxybutanoate
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It has been shown in adult humans that daily administration of (R)-3-hydroxybutyl (R)-3hydroxybutanoate can safely induce ketosis while on a normal diet over 28 days of
administration.97,98
A final set of ketogenic compounds that have been used to induce ketosis are salts
generated from racemic b-hydroxybutyrate. Most commonly, these are sodium, potassium, and
calcium salts (Fig. 1.18). In studies in rats fed a normal diet and supplemented with these salts, a
small increase in ketone body concentration in the blood was observed. Mineral salts of bhydroxybutyrate can induce ketosis, but the amounts required can lead to deleterious
gastrointestinal effects due to high levels of sodium.99

Figure 1.18: b-Hydroxybutyrate Mineral Salts

The use of these synthetic ketogenic compounds to supplement a normal diet has not only
shown the capability to induce ketosis, but also consequently decrease blood glucose
concentration without affecting triglyceride or cholesterol levels.6 (±)-1,3-Butanediol
acetoacetate diester has been shown to suppress seizure activity in rats.100 Combining (±)-1,3butanediol acetoacetate diester with the ketogenic diet was shown to slow cancer growth in
mice.5 Like the benefits of the ketogenic diet itself, the research into the use of synthetic
ketogenic compounds to supplement a normal diet is promising but is in its infancy. Similarly,
the variety of synthetic ketogenic compounds available is currently extremely limited to those
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just described, and thus there remains enormous potential to further expand on this through
targeted organic synthesis, to advance the breadth of research on ketogenic substances and their
use in improving human health.

1.9 Conclusions
From a chemist’s perspective, the field of synthetic ketogenic compounds is vast and
virtually unexplored. Palatability, caloric density, solubility, and gastrointestinal tolerance are
all attributes that can be improved. Advances in food formulation of lipid emulsions may be the
most obvious immediate options, but there is also a need for a significant expansion of edible,
ketogenic food substances whose structures, purities and biochemical effects are all documented
and controlled. Different functional groups linking together ketogenic groups, for instance,
could lead to a better controlled rate of generation of ketone bodies, perhaps even tissue-specific.
The possibilities are nearly endless and limited only by the imaginative abilities and restrictions
of chemical synthesis.
It is rare to find an area of research in the field of chemistry that is mostly unexplored.
Small-molecule synthesis is of particular interest to organic chemists for pharmaceutical
development across a broad spectrum of human diseases, but whether it is the ketogenic diet’s
origins as a medical treatment or the relative recency of much of the research, there has been
little effort put forth to explore the field of ketogenic compounds among synthetic organic
chemists. There is both commercial and biomedical potential to providing alternative methods of
inducing and maintaining ketosis, and novel synthetic ketogenic compounds could be an
important aspect of a solution.
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CHAPTER II

SYNTHESIS OF NOVEL KETOGENIC COMPOUNDS

2.1 Introduction
As discussed in Chapter I, triacylglycerides are the primary source of ketone bodies for a
person on the ketogenic diet. The fatty acids generated through both the digestion of dietary fats
and the hydrolytic breakdown of stored fats through lipolysis are subsequently broken down
through β-oxidation to release S-acetyl CoA, which can be used to generate ketone bodies
through ketogenesis. The glycerol backbone that is also released through lipolysis can either be
used by the liver to synthesize new triacylglycerides or converted to (R)-glyceraldehyde 3phosphate (Fig. 2.1).

Figure 2.1: Conversion of Glycerol to (R)-Glyceraldehyde 3-Phosphate
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(R)-Glyceraldehyde 3-phosphate is a metabolite in both the gluconeogenesis pathway and
the glycolysis pathway. Glycerol does not directly contribute to the generation of ketone bodies.
The fatty acids are the ketogenic groups of triacylglycerides, the glycerol is the frame.
With that mindset, synthetic ketogenic compounds could benefit from replacing the
backbone of a triglyceride with a ketogenic group and the fatty acids with alternative ketogenic
residues. It is important that it is tolerable to the body in high amounts and does not adversely
affect the health of those consuming it. In this chapter, several new alternatives are investigated.

2.2 Amino Acids as the Backbone of Ketogenic Compounds
As the building blocks of proteins, amino acids are a natural part of the diet. While most
amino acids are catabolized to glucose and would adversely affect ketosis in the body, leucine
and lysine are fully ketogenic and are converted directly to S-acetyl CoA as fuel for the Krebs
cycle.
Leucine has the benefit of being a branched chain amino acid, which plays a prominent
role in muscle repair and is a common commercial exercise supplement.101 Leucine has also
been shown to increase ketone body concentrations in the blood when taken in high amounts.102
For these reasons, its use in the synthesis of novel ketogenic compounds was explored.

2.3 Synthesis of Ketogenic Peptides
Short-chain peptides of leucine were synthesized to examine whether the chain length
would affect their metabolism or the level of ketone bodies in the blood. While peptide
chemistry is a vast and well-researched field, these compounds would need to be synthesized in a
large enough yield to allow for in vivo testing.
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N-Boc-protected L-leucine (Boc-Leu-OH) (1 equiv.) was added at room temperature to
diisopropylethylamine (1.2 equiv.) in methylene chloride. The t-butyl ester of L-leucine (H-LeuOtBu) (1 equiv.) was added, followed by the coupling reagent 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) (1.2 equiv.). The reaction was allowed to stir for sixteen hours
before the reaction mixture was washed with 1 N HCl and the solvent removed under reduced
pressure. Flash column chromatography using 1:3 ethyl acetate:hexane gave the protected
dileucine 1 as a white solid, which was immediately deprotected.

Scheme 2.1: Synthesis of Boc-Leu-Leu-OtBu (1)

The protected dileucine 1 was put under inert conditions and 4.0 M hydrochloric acid in
dioxane was added via syringe. The solution was allowed to stir overnight before the solvent
was removed under reduced pressure. The resulting oil was redissolved in chloroform and dried
under reduced pressure several times to give dileucine 2 as an off-white solid (0.9122 g, 37%).
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Scheme 2.2: Deprotection of Boc-Leu-Leu-OtBu (1) to form Dileucine●HCl (2)

A chain of three leucine residues was synthesized by first generating protected dileucine.
N-Fmoc-protected L-leucine (Fmoc-Leu-OH) was coupled to L-leucine t-butyl ester using the
same reaction conditions as Scheme 2.1. Fmoc-Leu-Leu-OtBu was collected as a yellow oil
(2.2647 g, 54.1%).

Scheme 2.3: Synthesis of Fmoc-Leu-Leu-OtBu (3)
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The Fmoc protecting group was removed by adding the product to a 1:3 solution of
diethylamine in acetonitrile. The solution was stirred for ninety minutes at room temperature
before the solvent was removed under reduced pressure. The crude product was redissolved in
75 mL chloroform, which was then removed under reduced pressure to generate the amine 4 as
an off-white solid (0.48 g, 36.9%).

Scheme 2.4: Fmoc Deprotection of Fmoc-Leu-Leu-OtBu (3) to Generate H-Leu-Leu-OtBu (4)

The amine 4 was then added to methylene chloride along with 1 equivalent of Boc-LeuOH and 1.2 equivalents of diisopropylethylamine. The mixture was stirred until dissolved, then
1.2 equivalents of EDC was added and the solution was allowed to stir overnight at room
temperature. The solvent was removed under reduced pressure and the resulting oil was purified
via flash column chromatography using 1:3 ethyl acetate:hexane to collect the protected
trileucine 5 as an off-white solid after the solvent was removed under reduced pressure.
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Scheme 2.5: H-Leu-Leu-OtBu (4) and Boc-Leu-OH Coupling

The Boc-Leu-Leu-Leu-OH (5) was put under inert conditions and dissolved in 10 mL of
4.0 M HCl in 1,4-dioxane and allowed to stir overnight. The volatiles and solvent were removed
under reduced pressure, and the product was redissolved in 100 mL and dried under reduced
pressure three times. The product was put under high vacuum to remove any remaining 1,4dioxane. Trileucine HCl salt (6) was collected as a white solid (0.916 g).

Scheme 2.6: Boc-Leu-Leu-Leu-OtBu (5) Deprotection
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These procedures could have been adapted to longer peptides or solid phase synthesis
methods could have been used, but the decrease in yield and exponential increase in number of
synthesis steps that comes with increasing the peptide length decreased the possible benefits that
would come from longer ketogenic amino acid chains.
Likewise, while lysine is also a fully ketogenic amino acid, the amine side chain
increases the need for protection and deprotection, increasing the number of steps and decreasing
the yield. Lysine chains of 2-5 amino acid length are also available commercially, although they
are relatively expensive. Instead, emphasis was put on using L-leucine as a scaffold for
ketogenic side groups attached by an amide bond.

2.4 N-Acyl Amino Acids
One of the simplest ketogenic groups are fatty acids. Triacylglycerides in the diet and
adipose tissue are comprised of three fatty acid chains of various lengths, and are hydrolyzed to
generate fatty acids that can be broken down into S-acetyl CoA through fatty acid b-oxidation in
the Krebs cycle. Fatty acids are inexpensive and commercially available.
Using leucine as a scaffolding, the simplest derivatization to increase its ketogenic
capabilities would be to add a fatty acid to the nitrogen. These compounds are known as N-acyl
amino acids. Coupling a fatty acid onto the amine of leucine via an amide bond mimics the
chemistry involved in peptide synthesis, and similar methods can be employed.
There are examples of N-acyl amino acids in the body, primarily as endogenous signaling
molecules. N-Arachidonylglycine in particular has received a lot of attention in recent years as a
metabolite of the endocannabinoid anandamide and its role in pain inhibition (Fig. 2.2).103,104
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Figure 2.2: N-Arachidonylglycine

While more than 70 N-acyl amino acids have been identified in the human body, most of
them contain long unsaturated fatty acids (primarily 16-22 carbons).105,106

2.4.1 Synthesis of N-Acyl Amino Acids
As discussed in Chapter 1, medium-chain triacylglycerides are beneficial to those on the
ketogenic diet because medium-chain fatty acids do not require active transport into the liver.86,87
N-Acyl amino acids consisting of medium-chain saturated fatty acids do not appear to play a
major role as neurotransmitters in the body. As such, their use was emphasized during synthesis
in this research project.
In order to understand the effects different amino acids and different length fatty acids, a
panel of compounds was synthesized following the same general two-step procedure (Scheme
2.7). First, an amide bond was formed between a fatty acid and an O-protected amino acid.
Then, the O-protecting group was removed to generate the N-acyl amino acid.

Scheme 2.7: General Synthesis of N-Acyl Amino Acids
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Three different coupling reagents were tested in the coupling of octanoyl acid and t-butyl
L-leucine ester: dicyclohexylcarbodiimide (DCC), 1-[bis(dimethylamino)methylene]-1H-1,2,3triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU), and 1-ethyl-3-(3dimethylaminopropyl)carbodiimide (EDC). These three were selected due to their availability
and common use in peptide chemistry.
DCC is often used to synthesize esters via Steglich esterification, but can also be used to
form amide bonds. Octanoic acid (1 equiv.), t-butyl L-leucine ester (1 equiv.) and DCC (2
equiv.) were added to methylene chloride and stirred overnight (Scheme 2.8). The mixture was
filtered and the solvent was removed under reduced pressure to give a yellow oil. The product
was a mixture of different compounds, and further purification via column chromatography
would have been necessary.

Scheme 2.8: DCC Coupling of Octanoic Acid and t-Butyl L-Leucine Ester

HATU is another common coupling reagent in peptide chemistry. Octanoic acid (1
equiv.), HATU (1 equiv.), and diisopropylethylamine (DIPEA) (2 equiv.) were dissolved in
acetonitrile and stirred for fifteen minutes (Scheme 2.9). Then, t-butyl L-leucine ester (1 equiv.)
was added and stirred overnight. The resulting solution was diluted with ethyl acetate and
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washed with a 1M HCl solution and with brine, dried over sodium sulfate, and dried under
reduced pressure to generate an amber oil that contained the product but was not pure (as
determined by 1H NMR).

Scheme 2.9: HATU Coupling of Octanoic Acid and t-Butyl L-Leucine Ester

The final coupling reagent tested was EDC. The t-butyl L-leucine ester (1 equiv.) was
added with 4-dimethylaminopyridine (DMAP) (1.3 equiv.) to methylene chloride and stirred
until dissolved (Scheme 2.10). Octanoic acid (1 equiv.) was added and stirred for fifteen
minutes, then EDC (1.3 equiv.) was added and the mixture was sealed and stirred overnight. The
reaction solution was then washed with a 10% citric acid solution, water, saturated sodium
bicarbonate solution, and brine. Then, the organic layer was dried over sodium sulfate and
removed under reduced pressure to give the O-protected fatty amide amino acid in good yield
(88%).
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Scheme 2.10: EDC Coupling of Octanoic Acid and t-Butyl L-Leucine Ester

1

H NMR spectroscopy confirmed the product was obtained with high purity (Fig. 2.3).

Figure 2.3: 1H NMR Spectrum of N-Octanoyl-L-Leucine t-Butyl Ester
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This was the method that was used for the coupling of different amino acids and fatty
acids (Scheme 2.11).

Scheme 2.11: General Coupling of t-Butyl L-Leucine Ester to Fatty Acid

The second step in this synthesis is the deprotection of the t-butyl esters. Acids in
organic solvents are the most prevalent method to remove t-butyl esters, and two different
methods were tested. A 4 M solution of hydrochloric acid in 1,4-dioxane is a slightly slower
method and seemed to only give partial deprotections even after 24 hours, while high
concentrations of trifluoroacetic acid in methylene chloride were shown to be quicker and more
effective.
The t-butyl ester was most effectively removed by stirring in a 1:1 trifluoroacetic
acid:methylene chloride solution under inert atmospheric conditions (nitrogen) for one hour
(Scheme 2.12). The solvent and volatiles were removed under reduced pressure, and the
resulting oil was dried under a continuous flow of air. Afterwards, the resulting crystalline solid
was dissolved in methylene chloride, washed with 1 partition of water and then brine, and dried
over anhydrous sodium sulfate. The organic solvent was removed under reduced pressure to
give the desired N-acyl amino acid.
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Scheme 2.12: Deprotection of t-Butyl L-Leucine Ester

This method of coupling and deprotection was used to synthesize a panel of N-acyl Lleucine compounds with fatty acid chains of different lengths (Table 2.1). For deprotection of Npropanoyl-L-leucine (7), no product was recovered, possibly due to the increased solubility of
shorter chain N-acyl amino acids to the aqueous workup.

Table 2.1: Fatty Acids used for N-Acyl L-Leucine Syntheses
Fatty Acid

Common Name

IUPAC Name

Product Name

Yield

Formula
CH3(CH2)3COOH

valeric acid

pentanoic acid

15 N-pentanoyl-L-leucine

67%

CH3(CH2)4COOH

caproic acid

hexanoic acid

16 N-hexanoyl-L-leucine

73%

CH3(CH2)5COOH

enanthic acid

heptanoic acid

17 N-heptanoyl-L-leucine

77%

CH3(CH2)6COOH

caprylic acid

octanoic acid

18 N-octanoyl-L-leucine

29%

CH3(CH2)7COOH

pelargonic acid

n-nonanoic acid

19 N-nonanoyl-L-leucine

87%

CH3(CH2)8COOH

capric acid

decanoic acid

20 N-decanoyl-L-leucine

86%

CH3(CH2)10COOH

lauric acid

dodecanoic acid

21 N-dodecanoyl-L-leucine

90%

The coupling of glycine to fatty acids was accomplished in the same manner. The fatty
acid (1 equiv.) was added to a solution of 4-dimethylaminopyridine (1.3 equiv.) in methylene
chloride and stirred until dissolved (Scheme 2.13). The t-butyl glycine ester (1 equiv.) was then
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added and stirred to dissolve. Finally, EDC (1.3 equiv.) was added and the reaction was capped
and stirred at room temperature overnight before acid-base workup.

Scheme 2.13: General Coupling of t-Butyl Glycine Ester to Fatty Acid

The fatty amide glycine t-butyl ester was then deprotected using a 1:1 mixture of
trifluoroacetic acid and methylene chloride (Scheme 2.14). The products were collected as white
or off-white solids.

Scheme 2.14: Deprotection of t-Butyl Glycine Ester

This general method was used to synthesize a panel of N-acylglycine compounds with
fatty acid chains of different lengths (Table 2.2).
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Table 2.2: Fatty Acids used for N-Acylglycine Syntheses
Fatty Acid

Common Name

IUPAC Name

Product Name

Yield

CH3(CH2)4COOH

caproic acid

hexanoic acid

30 N-hexanoylglycine

13%

CH3(CH2)5COOH

enanthic acid

heptanoic acid

31 N-heptanoylglycine

25%

CH3(CH2)6COOH

caprylic acid

octanoic acid

32 N-octanoylglycine

17%

CH3(CH2)7COOH

pelargonic acid

n-nonanoic acid

33 N-nonanoylglycine

4.6%

CH3(CH2)8COOH

capric acid

decanoic acid

34 N-decanoylglycine

72%

CH3(CH2)10COOH

lauric acid

dodecanoic acid

35 N-dodecanoylglycine

9.0%

Formula

2.5 Diketopiperazines in Nature
A variation on using a single amino acid or its dipeptide as the scaffolding for synthetic
ketogenic compounds is the use of 2,5-diketopiperazines. Diketopiperazines are six-membered
rings containing two amides (Fig. 2.4).

Figure 2.4: Diketopiperazine Isomers

Derivatives of 2,5-diketopiperazine are naturally-occurring in a wide spectrum of
biologically active compounds.107 A number of drugs have been developed from natural
products that contain the 2,5-diketopiperazine group (Fig. 2.5).
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Figure 2.5: Examples of 2,5-Diketopiperazine Derivatives in Nature

Bicyclomycin was isolated from Stremptomyces sapporonesis and Streptomyces
aizumenses in 1972 and is used as a broad spectrum antibiotic.108 Epelsiban was developed
based on high-throughput screenings done by GlaxoSmithKline against common kinetoplastoids
in 2015.109 It is used as an oxytocin receptor antagonist to treat premature ejaculation in men and
to improve in vitro fertilization rates in women.110,111 Aplaviroc was developed as a treatment
for HIV, but studies were discontinued due to liver toxicity issues.112,113 The wide array of
bioactive compounds containing 2,5-diketopiperazines has made it an area of focus in synthetic
chemistry in recent years.114,115
2,5-Diketopiperazines as whole compounds consisting of a variety of amino acid residues
have been isolated in food products and in the human brain.116,117 There is evidence that 2,5diketopiperazines could act as detoxifying agents in the body, but the breakdown of these
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compounds in the body is not fully understood.118 However, it appears that 2,5diketopiperazines are tolerated by the body.

2.5.1 Synthesis of N,N’-Diacyl-2,5-diketopiperazines
The 2,5-diketopiperazines are commonly formed when the primary amine of a dipeptide
cyclizes with the carboxylic acid. They are often unwanted side products in the deprotection of
dipeptides, but diacylation of 2,5-diketopiperazines could generate two equivalents of fatty acid
upon hydrolysis (Fig. 2.6). Several of these compounds were synthesized with this in mind.

Figure 2.6: Hydrolysis of Acylated 2,5-Diketopiperazines

Commercially available piperazine-2,5-dione (1 equiv.) was added to a solution of 4dimethylaminopyridine (2.3 equiv.) in methylene chloride (Scheme 2.15). The fatty acid (2
equiv.) was added and stirred to dissolve. EDC (2.3 equiv.) was then added, and the mixture was
stirred overnight before an acid-base workup. The solvent was removed under reduced pressure
to generate the product as a white or off-white solid.
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Scheme 2.15: Synthesis of 1,4-Diketopiperazine Fatty Imides 36-38

2.6 Synthesis of N-Acetoacetyl L-Leucine
While fatty acid derivatives provide a ready comparison to dietary fats, the true
possibilities of synthetic ketogenic compounds is in the freedom to avoid the slow process of
lipolysis, ß-oxidation, and ketogenesis required to generate ketone bodies from dietary fats.
Instead, groups that can easily be converted to ketogenic bodies through hydrolysis or enzyme
interaction allow for the direct introduction of ketone bodies into the body.
The use of (±)-1,3-butanediol acetoacetate diester to increase ketone body concentration
in the blood is well studied.6 The formation of an acetoacetyl amide between leucine and t-butyl
acetoacetate was attempted in order to replicate this effect.

2.6.1 Coupling of L-Leucine Esters to t-Butyl Acetoacetate
Synthesizing an acetoacetyl amide presents several challenges. Transesterification
reactions are common and allow for a wide variety of conditions, catalysts, and reagents.120 In
contrast, the formation of an amide bond from an amine and an ester is much less common and
sometimes requires very specific conditions or expensive organometallic catalysts.121 In the field
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of peptide chemistry, alkyl esters are generally used as protecting groups because they are
unreactive.122 However, several methods were still attempted.
An adaptation of the transesterification reaction used to generate (±)-1,3-butanediol
acetoacetate diester was attempted first. L-Leucine t-butyl ester hydrochloride (1 equiv.) was
added to t-butyl acetoacetate (1 equiv.) and xylenes and heated (Scheme 2.16). The leucine ester
salt never dissolved and no t-butanol was collected. This was determined to be due to the lack of
a base to neutralize the hydrochloric acid.

Scheme 2.16: Attempted Thermal Coupling of t-Butyl Acetoacetate and L-Leucine t-Butyl Ester
Hydrochloride Salt

In order to neutralize the ammonium species, the procedure was repeated with base. LLeucine t-butyl ester hydrochloride (1 equiv.) and pyridine (1 equiv.) were added to t-butyl
acetoacetate (1 equiv.) and xylenes and heated (Scheme 2.17). However, once again, no tbutanol distillate was observed by Dean-Stark distillation.
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Scheme 2.17: Attempted Coupling of t-Butyl Acetoacetate and L-Leucine t-Butyl Ester
Hydrochloride Salt using Pyridine.

In order to verify that the t-butyl ester group on leucine was not interfering with the
coupling with t-butyl acetoacetate, L-leucine benzyl ester p-toluenesulfonic acid salt was used.
The free base was obtained by stirring in a saturated sodium bicarbonate solution for fifteen
minutes and extracting several times with methylene chloride. The organic layers were
combined, dried over sodium sulfate, and the solvent was removed under reduced pressure to
give L-leucine benzyl ester as a clear liquid, verified by 1H NMR spectroscopy (Fig. 2.7).
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Figure 2.7: 1H NMR Spectrum of L-Leucine Benzyl Ester

This sample (1 equiv.) was added to t-butyl acetoacetate (1 equiv.) in xylenes and
refluxed at 120°C (Scheme 2.17). After four hours, the reaction was removed from heat. Once
again, there appeared to be no reaction taking place, as no t-butanol was distilled off. The 1H
NMR spectrum showed t-butyl acetoacetate and what appeared to be aliphatic remnants of the
amino acid as alkyl peaks. The benzyl ester group was not visible in the 1H NMR spectrum.
The amino acid did not appear to be thermally stable at the temperatures of the experiment.
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Scheme 2.18: Attempted Thermal Coupling of t-Butyl Acetoacetate and L-Leucine Benzyl Ester

Although there has been some research done on the thermal stability of common amino
acids, there does not appear to be any evidence in the literature concerning the thermal stability
of common amino acid esters.123 To test the thermal stability of the benzyl and t-butyl esters of
leucine, the free bases were generated from the salts and dissolved in xylenes. They were heated
to 120°C and left to stir overnight. They were analyzed using 1H NMR spectroscopy, and no
amino ester remained in the spectrum.
In order to avoid degradation of the amino ester, milder conditions were explored. LLeucine t-butyl ester hydrochloride was dissolved in a minimal amount of water and saturated
sodium bicarbonate solution was added until precipitation occurred. The precipitate was
extracted several times with methylene chloride, the organic layers were combined and dried
over sodium sulfate, and the organic solvent was removed under reduced pressure to generate Lleucine t-butyl ester as a clear liquid, verified by 1H NMR spectroscopy (Fig. 2.8).
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Figure 2.8: 1H NMR Spectrum of L-Leucine t-Butyl Ester

The sample (1 equiv.) and methyl acetoacetate (1 equiv.) were dissolved in methylene
chloride and allowed to stir for several days (Scheme 2.19). Aliquots were taken every 24 hours,
dried under reduced pressure, and analyzed by 1H NMR. After four days, no methyl acetoacetate
was present. The organic solvent was evaporated under reduced pressure to give a clear oil as a
product.
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Scheme 2.19: Attempted Synthesis of N-Acetoacetyl L-Leucine t-Butyl Ester Under Mild
Conditions

1

H NMR analysis did not show methyl acetoacetate or L-leucine t-butyl ester, but did not

match the expected data for N-acetoacetyl L-leucine (Fig. 2.9).

Figure 2.9: 1H NMR Spectrum of Attempted Synthesis of N-Acetoacetyl L-Leucine t-Butyl
Ester
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In order to further verify if the N-acetoacetyl leucine ester had formed, deprotection of
the t-butyl ester was attempted. The product (1 equiv.) from the reaction was dissolved in dry
methylene chloride, put under inert conditions, and charged with an equal volume of
trifluoroacetic acid (TFA) (Scheme 2.20). The solution was allowed to stir for two hours before
the solvent was removed under reduced pressure. The off-white crystalline product was dried
under a flow of air overnight. The solid material was redissolved in methylene chloride and
washed twice with 25 mL of water in an attempt to purify the product. The solvent was removed
under reduced pressure to give the product as an oil. 1H NMR showed the absence of the t-butyl
ester, as expected, as well as a large amount of methyl acetoacetate (Fig. 2.10). It appeared that
the TFA deprotection had cleaved the t-butyl ester, and L-leucine had been lost in the aqueous
layer during purification. To explain the formation of the methyl ester from this deprotection, the
original adduct of the N-acetoacetylation reaction was clearly not the expected product.

Scheme 2.20: Attempted Deprotection of N-Acetoacetyl L-Leucine t-Butyl Ester
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Figure 2.10: 1H NMR Spectrum of the Product Obtained from Attempted Deprotection of the
Crude N-Acetoacetyl L-Leucine t-Butyl Ester

The sensitivity of the product to the deprotection of the t-butyl ester was inconsistent with
the expected stability of an amide bond. Based on this and the NMR data, it was determined that
an enamine had formed between methyl acetoacetate and L-leucine t-butyl ester (Scheme 2.21).
While it is possible that either the Z or E isomers could form, hydrogen bond interactions
between the amine and the oxygen on the carbonyl make the Z isomer the more likely product.
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Scheme 2.21: Synthesis of t-Butyl (Z)-(4-Methoxy-4-oxobut-2-en-2-yl)-L-Leucinate Under Mild
Conditions

While this was an unintentional product, it is possible that this product could be
ketogenic. Enamines are very sensitive to acid and could generate methyl acetoacetate and Lleucine t-butyl ester during digestion. If the esters on these groups were cleaved by the body, it
could lead to an increase in ketone body concentration from acetoacetic acid.
The reaction was run again at an increased temperature and without solvent to optimize
the synthesis of the enamine. The free base of L-leucine t-butyl ester (1 equiv.) was added to
methyl acetoacetate (1 equiv.) and allowed to stir at 50°C overnight (Scheme 2.22). 1H NMR
showed no methyl acetoacetate. The enamine product 39 was not purified further.

Scheme 2.22: Synthesis of t-Butyl (Z)-(4-Methoxy-4-oxobut-2-en-2-yl)-L-Leucinate (39)
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The same reaction was also done with the L-leucine benzyl ester. The free L-leucine
benzyl ester (1 equiv.) was added to methyl acetoacetate (1 equiv.) and allowed to stir at 50°C
overnight (Scheme 2.23). The enamine product 40 was not purified further (Fig. 2.11).

Scheme 2.23: Synthesis of Benzyl (Z)-(4-Methoxy-4-oxobut-2-en-2-yl)-L-Leucinate (40)

Figure 2.11: 1H NMR Spectrum of Benzyl (Z)-(4-Methoxy-4-oxobut-2-en-2-yl)-L-Leucinate (40)
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Deprotection of the benzyl ester was attempted by hydrogenation. The enamine (40) (1
equiv.) and 10% Pd/C (200 mg/mmol) were dissolved in dry ethyl acetate and flushed with
nitrogen gas. Hydrogen gas was added via balloon and the reaction was allowed to stir at room
temperature for 4 hours. The reaction mixture was filtered through celite and the organic solvent
was removed under reduced pressure to give an off-white product. 1H NMR showed methyl
acetoacetate in excess (Fig. 2.12), indicating a cleavage of the enamine.

Figure 2.12: 1H NMR Spectrum of Methyl Acetoacetate from Attempted Deprotection of Benzyl
(Z)-(4-Methoxy-4-oxobut-2-en-2-yl)-L-Leucinate (40)
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2.6.2 Direct Acetoacetylation of L-Leucine
The availability of acetoacetate esters makes them appealing reagents for the synthesis of
acetoacetate derivatives. One of the simplest ways to generate an amide from an ester is by first
converting the ester to a carboxylic acid or an acyl chloride.122 However, acetoacetic acid is
difficult to isolate due to its instability as it quickly decarboxylates to acetone. Similarly,
acetoacetyl chloride is unstable and quickly degrades at room temperature.124
In order to overcome these limitations, several alternative methods for acetoacetylation
have been developed. The classical method for acetoacetylation is through the use of diketene,
the dimerization product of ketene generated at temperatures above 600°C from acetone.125
Diketene is sensitive to nucleophilic attack and has been used to acetoacetylate alcohols and
amines (Scheme 2.24).126

Scheme 2.24: N-Acetoacetylation of 2-Aminoindane Using Diketene

Despite its use in chemical synthesis, diketene is no longer shipped commercially due to
its toxicity and lachrymatory properties.127 It must be generated on site. Because of the
difficulty in doing so and safety concerns, this reagent was not used.
In order to overcome the difficulties found in using diketene as a reagent in
acetoacetylation, several alternatives were developed. One group was the acetoacetate esters
discussed previously. Another is 2,2,6-trimethyl-4H-1,3-dioxin-4-one, an adduct of diketene and
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adduct developed in 1952 that has been shown to function in a similar manner to diketene in the
acetoacetylation of alcohols and amines (Scheme 2.25).128

Scheme 2.25: Reported Acetoacetylation of L-Phenylalanine Methyl Ester using 2,2,6Trimethyl-4H-1,3-dioxin-4-one

The acetoacetylation of an amino ester using this method was promising, and despite
concerns about thermal stability, this method was attempted. L-Leucine methyl ester
hydrochloride was dissolved in a minimal amount of water and saturated sodium bicarbonate
solution was added, but no precipitation occurred. The neutralized L-leucine methyl ester was
extracted several times with methylene chloride, the organic layers were combined and dried
over sodium sulfate, and the organic solvent was removed under reduced pressure to yield Lleucine methyl ester as a clear liquid verified by 1H NMR (Fig. 2.13).
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Figure 2.13: 1H NMR Spectrum of L-Leucine Methyl Ester

The product (1 equiv.) and 2,2,6-trimethyl-4H-1,3-dioxin-4-one (1 equiv.) were dissolved
in xylenes and heated to 150°C for 30 minutes (Scheme 2.26).
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Scheme 2.26: Attempted Acetoacetylation of L-Leucine Methyl Ester using 2,2,6-Trimethyl-4H1,3-dioxin-4-one

The reaction mixture was allowed to cool to room temperature and the organic solvent
was removed via rotary evaporation. 1H NMR did not show the presence of an acetoacetylated
product (Fig. 2.14).

Figure 2.14: 1H NMR Spectrum of Attempted Acetoacetylation of L-Leucine Methyl Ester
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Because of the difficulty in synthesizing N-acetoacetyl L-leucine, the synthesis of other
compounds were pursued instead.

2.6 Acetoacetate Esters of Glycerol
As mentioned previously, acetoacetate esters have been shown to increase ketone body
concentration in the blood to levels indicative of ketosis.6 In particular, (±)-1,3-butanediol
acetoacetate diester has been effective because not only does it generate two equivalents of
acetoacetic acid upon hydrolysis, but (±)-1,3-butanediol is also converted to ketone bodies in the
liver. However, the use of other acetoacetate esters remains largely unexplored.
Dietary fats primarily consist of three fatty acids bound to glycerol by ester bonds.
Glycerol is an appealing scaffolding for new synthetic ketogenic compounds because of high
tolerability in the body and the presence of three functional groups to derivatize. A mixture of
the monoacetoacetate ester derivatives of glycerol were synthesized using diketene in 1979 as a
method for supplying calories in the forms of both fat and carbohydrates (Fig. 2.15).129

Figure 2.15: Glycerol Acetoacetate Monoesters

Studies of these compounds in mice showed that they did increase ketone body
concentrations in the blood of rats to levels consistent with ketosis, although this was done in
conjunction with calorie restriction so it is difficult to assess how much of an effect this
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compound would have on ketone body concentration in the blood while on a normal diet. On top
of this, one of the metabolic fates of glycerol is the synthesis of glucose through the
gluconeogenesis pathway. A glycerol acetoacetate monoester would generate one equivalent
each of acetoacetic acid and glycerol upon hydrolysis, which would decrease the effective
ketogenicity of the compound.
With this in mind, the glycerol acetoacetate triester was synthesized. Glycerol (1 equiv.)
and t-butyl acetoacetate (3.1 equiv.) were dissolved in xylenes. The flask was equipped with a
Dean-Stark trap and condenser and the solution was heated to 150°C. After distillation of tbutanol (3 equiv.) was complete, the reaction was removed from heat and excess t-butyl
acetoacetate was removed via rotary evaporation to give the product 41 as a clear oil (Scheme
2.27).

Scheme 2.27: Synthesis of Propane-1,2,3-triyl tris(3-Oxobutanoate) (41) in Refluxing Xylenes

The reaction was also run without solvent in an effort to make purification simpler
(Scheme 2.28). 1H NMR analysis showed signals for the product in good yield with only trace
amounts of t-butyl acetoacetate (Fig. 2.16).
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Scheme 2.28: Synthesis of Propane-1,2,3-triyl tris(3-Oxobutanoate) (41) under Neat Conditions

Figure 2.16: 1H NMR Spectrum of Glycerol Acetoacetate Triester

2.7 Conclusions
In order to demonstrate the synthetic possibilities for ketogenic compounds, a variety of
compounds that could display ketogenicity were developed (Fig. 2.17). Panels of N-acyl amino
62

acids were synthesized to demonstrate the effects fatty acid chain lengths and amino acid
selection may have on ketogenicity. Several N-acylated 2,5-diketopiperazines were synthesized
to study the role cyclic peptides could play in novel ketogenic compounds. Enamines of
acetoacetate methyl ester and leucine benzyl and t-butyl esters were synthesized. Lastly,
glycerol acetoacetate triester was synthesized in an effort to improve ketogenicity compared to
the acetoacetate esters currently in use.

Figure 2.17: Novel Synthetic Ketogenic Compounds

While further testing needs to be done to determine whether these compounds could be
used to increase ketone body concentration in the blood, they serve as an excellent example of
the broad possibilities available in the field of synthetic ketogenic compounds.
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CHAPTER III

ASSAYS OF ENZYMATIC HYDROLYSIS OF NOVEL KETOGENIC COMPOUNDS

3.1 Introduction
These studies into the design and synthesis of potential ketogenic compounds require a
reliable, simple, and cost-effective way to determine if they are capable of providing energy for
the body in the form of ketone bodies. For most of its history, the ketogenic diet has relied on
informal testing on patients in clinical settings to assess whether a variable such as a high fat
food diet has a detectible effect on ketogenic performance or on human health.
The first research using animal models studying the effects of synthetic ketogenic
compounds was done in the 1970s and 1980s (Fig. 3.1). Interest in alternatives to dietary fats
that could be given to patients intravenously led to the synthesis of several possible candidates
whose effectiveness was measured in different animals.
The monoacetoacetate esters of glycerol were synthesized in 1979 as a way to deliver
calories in the form of both glucose and ketone bodies intravenously.129 Male Holtzman rats
were given either the monoacetoacetyl glyceride mixture or glucose intravenously alongside a
low-calorie diet for 7 days, after which the concentration of glucose, pyruvate, acetoacetate, and
R-b-hydroxybutyrate in the blood was measured. Similarly, mixtures of (±)-1,3-butanediol
acetoacetate diester and the monoesters were synthesized to deliver calories as ketone bodies and
given to male Yorkshire-Landrace pigs.90 Animals were fasted overnight and given the
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ketogenic compound intravenously over 3 hours. Blood samples were taken at various times
over 5 hours and the concentrations of glucose, acetoacetate, R-b-hydroxybutyrate, S-bhydroxybutyrate, pyruvate, and lactate were measured. An increase in ketone body
concentrations was observed for both these experiments, but the emphasis of the testing was
placed on the tolerance of the compounds and their effects on the health of the animals.

Figure 3.1: Early Synthetic Ketogenic Compounds

While earlier animal testing was primarily concerned with the overall effect of these
compounds on blood metabolite profiles to justify their use in intravenous feeding, increased
interest in the ketogenic diet has led to new interest in animal testing that focuses exclusively on
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ketone body concentrations in the blood. As an example of this, Sprague-Dawley rats were used
to show ketogenic supplements could induce ketosis on a normal diet without fasting in 2016 by
D’Agostino.6
Testing with animal models requires specialized facilities, training, and development of
an approved experimental protocol. In addition, initial investigations in synthetic organic
chemistry are generally done on a smaller scale than that often required to provide sufficient
amounts of a new test compound for in vivo analysis. These are obvious logistical limitations to
the creation of new organic molecules intended to be useful ketogenic supplement replacements.
The synthetic compound must be able to biochemically convert to substances that are, or
will lead to, ketogenic metabolites used in the target tissue or organ. Consequently, compounds
that are unable to be chemically transformed to these products will not affect the concentration of
ketone bodies in the blood. These concerns require a simple, efficient method for testing the
efficacy of synthetic compounds to serve as a source of ketone bodies or ketogenic material. The
first step in assessing the ketogenic potential of compounds, then, is to determine if they are
susceptible to hydrolysis to produce ketone bodies or ketogenic products under conditions that
model those in digestion. In the case of the N-fatty acyl amino acids described in Chapter 2, this
would involve the enzymatic hydrolysis of the amide to the fatty acid and free amino acid,
shown below (Fig. 3.2).

Figure 3.2: Enzymatic Hydrolysis of N-Acyl Amino Acids
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In this chapter, in vitro testing was performed using commercially available hydrolase
enzymes to show if the compounds synthesized in this study might be metabolized in the body to
generate ketogenic products as a justification for further testing using an appropriate animal
model.

3.2 Enzymes
Enzymology plays a key role in understanding the biochemistry of the human body, and
as such, enzyme assays have a long history in the laboratory. However, the use of enzymes in
synthetic organic chemistry is generally limited to catalytic roles. Enzyme assays provide a
simple way to show the breakdown of new synthetic compounds into their ketogenic components
without requiring large-scale animal testing. To accomplish this, enzymes that can accept a
broad variety of substrates were chosen.
Carboxylesterases play an important role in the hydrolysis of esters, amines, and
thioesters in the liver.130,131 Carboxylesterase from porcine liver (PLE) was first isolated in 1961
by Adler and Kistiakowsky.132 Its biological activity, three-dimensional structure and substrate
selectivity were delineated in the years that followed.133 A serine hydrolase, PLE has been
shown to tolerate a broad variety of substrates of different sizes and functional groups including

b-lactam rings and diesters.134 It is commonly used today to catalyze asymmetric hydrolysis of
meso diesters.135-137 However, its acceptance of a broad range of substrates makes it an ideal
candidate to evaluate the enzymatic hydrolysis of new ester or amide compounds.138
Lipases also show enzymatic activity across a broad range of substrates and their
importance in the metabolism of dietary fat justify their inclusion when evaluating the enzymatic
hydrolysis of novel synthetic ketogenic compounds.139 Burkholderia cepacian lipase was first

67

cloned from Burkholderia cepacian bacteria in 1991.140 Sold under the name Amano PS lipase,
it is commonly used in the synthesis of enantiomerically pure compounds and has been shown to
hydrolyze triacylglycerides.141
These two enzymes were chosen based on their commercial availability and to mimic
digestion in the body. The role of lipases in the digestion of dietary fats has been discussed and
it was thought that their broad substrate specificity might catalyze the hydrolysis of N-acyl amino
acids. Likewise, carboxylesterases in the liver have been shown to hydrolyze a variety of
exogenous and endogenous compounds.142 Compounds that are not metabolized through
digestion are often broken down in the liver to usable products or waste, and it was thought that
enzymes involved in this process would provide the strongest enzymatic activity across the
broadest range of synthetic substrates.

3.3 Enzyme Assays
Analysis of enzyme activity often requires the use of specialized equipment that a
synthetic organic chemistry laboratory may not have. UV spectroscopy, gas chromatography,
and liquid chromatography-mass spectrometry are common analysis methods in biology and
biochemistry laboratories but may not be optimal options for these assays. With that in mind, a
protocol for testing the hydrolytic stability of the synthetic compounds prepared in Chapter 2 was
developed for use with PLE and Amano PS lipase.
A protocol developed for the characterization of a Penicillium sp. lipase using
triglycerides was adapted to suit the alternative substrates and analysis method used.143,144 NAcyl amino acids generally have poor solubility in water, as they share many of the same
physical properties as dietary fats. To remedy this, the substrates to be tested were dissolved in a
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small amount of an organic solvent (dimethylsulfoxide) before an aqueous buffer solution was
added dropwise. The samples were heated to the optimum temperature according to the enzyme
that was used for the assay based on the information provided by the manufacturer. Aliquots
taken periodically during the course of the hydrolysis were extracted from the aqueous buffer
solution with ethyl acetate several times, then dried by rotary evaporation under vacuum.

3.3.1 Development of an Analytical Procedure to Follow Enzymatic Hydrolysis
1

H NMR spectroscopy was used to analyze the amount of substrate hydrolyzed by the

enzyme by comparing the integration values of the unique protons. 1H NMR spectroscopy was
chosen for analysis based on its availability and the speed at which analysis can be done. While
it does require larger sample concentrations than other common enzyme activity analysis
techniques like HPLC, the synthesis of N-acyl amino acids is relatively inexpensive and can be
done on large enough scale that this is not an issue.
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Figure 3.3: 1H NMR Spectral Analysis of Enzymatic Hydrolysis of N-Acylated Amino Acids

The hydrolysis of N-acyl amino acids over times is apparent from the emergence of peaks
corresponding to the free fatty acids (Fig. 3.3). The 1H NMR signal for the protons on the α
carbon to the carboxylic acid in fatty acids occur further downfield than those on the α carbon to
the amide in N-acyl amino acids. The integration across the peaks gives the relative amounts of
both the substrate and the free fatty acid and comparing these numbers gives the amount of
substrate enzymatically hydrolyzed at that time. This also provides a clear visual representation
of the hydrolysis of the substrate and the emergence of the free fatty acid (Fig. 3.4).
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Figure 3.4: 1H NMR Spectral Analysis of Enzymatic Hydrolysis of N-Octanoyl-L-Leucine at
Different Time Points

3.3.2 Development of Protocol for Porcine Liver Esterase Assay of N-Acylated Amino Acids
Initial testing was done in order to determine a range of times where the hydrolysis of Nacylated amino acids could be measured. Since the rate of hydrolysis is dependent on the
concentration of the enzyme, initial testing was done to determine a concentration at which the
time point where half of the substrate had been hydrolyzed (t1/2) could be found.
Three samples of N-octanoyl-L-leucine (11.1 mg, 0.043 mmol) were dissolved in
dimethyl sulfoxide (DMSO) (0.5 mL). A 50 mM phosphate buffer (2.0 mL) at pH 7 was added
dropwise while spinning at 360 Hz to prevent the substrate from crashing out of solution.
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Different concentrations of PLE solutions (1 mg/mL, 3 mg/mL, 10 mg/mL) in 50 mM phosphate
buffer at pH 7 were added dropwise (1 mL). The samples were stirred at 120 Hz and aliquots
(0.5 mL) were taken at T = 4, 24, and 48 hours.
The percentage of N-octanoyl-L-leucine hydrolyzed for each quantity of enzyme was
plotted against time to give the rate of hydrolysis over time (Fig. 3.5).

Effects of Porcine Liver Esterase Concentration on Activity
Against N-Octanoyl-L-Leucine
Amount of Substrate Hydrolyzed (%)

1
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Figure 3.5: Effects of Porcine Liver Esterase Concentration on Activity Against N-Octanoyl-LLeucine

Based on the initial concentration testing, 3 mg of PLE was used in subsequent testing.
The times at which aliquots were taken were determined based on further preliminary
experiments across all compounds to be tested. Each of the N-acyl amino acids (0.043 mmol)
that had been acquired in good yield in Chapter 2 were dissolved in DMSO (0.5 mL). A 50 mM
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phosphate buffer (2.0 mL) at pH 7 was added dropwise while spinning at 360 Hz to prevent the
substrate from crashing out of solution, and the solution was heated to 35°C. A solution of PLE
in phosphate buffer was prepared (3 mg/mL) and allowed to stir at 35°C for 30 minutes. The
PLE solution (1.0 mL) was added and aliquots (0.5 mL) were taken every 24 hours to determine
the rate of hydrolysis.
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Table 3.1: 1H NMR Integration Values for Preliminary Enzyme Assay

5
6
7
8
9
10
12

T=
1.00
1.00
1.00
1.00
1.00
1.00
1.00

24 hours
0.18 0.85
1.30 0.43
4.34 0.19
0.93 0.52
3.27 0.23
6.70 0.13
3.75 0.21

T=
1.00
1.00
1.00
1.00
1.00
1.00
1.00

48 hours
0.10 0.91
0.70 0.59
2.53 0.28
0.39 0.72
2.68 0.27
6.77 0.13
5.97 0.14

T=
1.00
1.00
1.00
1.00
1.00
1.00
1.00

72 hours
0.07 0.93
0.39 0.72
2.02 0.33
0.20 0.83
2.14 0.32
4.52 0.18
6.71 0.13

T=
1.00
1.00
1.00
1.00
1.00
1.00
1.00

96 hours
0.05 0.95
0.31 0.76
1.49 0.40
0.22 0.82
1.59 0.39
5.13 0.16
5.24 0.16

6
7
8
9
10
12

T=
1.00
1.00
1.00
1.00
1.00
1.00

24 hours
0.12 0.89
0.22 0.82
0.06 0.94
0.16 0.86
1.50 0.40
0.61 0.62

T=
1.00
1.00
1.00
1.00
1.00
1.00

48 hours
0.11 0.90
0.14 0.88
0.14 0.88
0.09 0.92
1.44 0.41
0.66 0.60

T=
1.00
1.00
1.00
1.00
1.00
1.00

72 hours
0.09 0.92
0.10 0.91
0.05 0.95
1.26 0.44
1.23 0.45
0.63 0.61

T=
1.00
1.00
1.00
1.00
1.00
1.00

96 hours
0.15 0.87
0.12 0.89
0.12 0.89
0.08 0.93
1.03 0.49
0.52 0.66

Glycine
FA Length

The percentage of substrate hydrolyzed for each compound was plotted against time to
give the rate of hydrolysis over time (Fig. 3.6 & Fig. 3.7).
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Preliminary Porcine Liver Esterase Activity on
N-Acyl-L-Leucine Compounds
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Figure 3.6: Preliminary Porcine Liver Esterase Activity on N-Acyl-L-Leucine Compounds

Preliminary Porcine Liver Esterase Activity on
N-Acylglycine Compounds
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Figure 3.7: Preliminary Porcine Liver Esterase Activity on N-Acylglycine Compounds
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Based on this data, it was clear that a large percentage of most substrates were
hydrolyzed within the first 24 hours. The times at which aliquots were taken for each N-acyl
amino acid were estimated based on these results. It was noted that DMSO was difficult to
remove and could make 1H NMR spectra challenging to analyze. Because of this, the amount of
organic solvent used to dissolve each substrate was reduced.

3.3.3 Porcine Liver Esterase Assay of Ketogenic Compounds
Below is a protocol for the porcine liver esterase hydrolysis assay for the synthetic
compounds, in this case, for N-hexanoylglycine:
Crude porcine liver esterase (9 mg, 27 units/mg) was dissolved in a 50 mM phosphate
buffer solution at pH=7 (3 mL) and allowed to stir for thirty minutes at 35°C. Three samples of
N-hexanoylglycine (33) (7.4 mg, 0.043 mmol) were each dissolved in DMSO (0.2 mL). 2.0 mL
of a 50 mM phosphate buffer solution at pH 7 was added dropwise to each sample while stirring
at 360 Hz. The spin was reduced to 120 Hz and the samples were heated to 35°C. The porcine
liver esterase solution (1 mL, 1 mg/mL) was added dropwise to each sample and the samples
were allowed to stir. Aliquots were taken at T = 1, 3, 5, 7, 9, and 24 hours. Aliquots were
washed three times with ethyl acetate (2 mL) and the organic layers were combined and
evaporated by rotary evaporation. The residue was taken up in CDCl3 and 1H NMR analysis was
performed using a 400 MHz NMR spectrometer.
For each compound, three individual assays were run at the same time, under identical
protocols. The amount of substrate was kept constant (0.043 mmol), and the times were based
on the preliminary data (Table 3.2). A positive control (ethyl butyrate) and a negative control
(N-hexanoylglycine in buffer solution without porcine liver esterase) were also used.
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Table 3.2: Amounts of Substrate and Aliquot Times for Pig Liver Esterase Assay of N-Alkyl
Amino Acids
Amino Acid

Fatty Acid Length

Substrate (mg)

Aliquot Times (hours)

Leucine

5

9.3

2

5

8

16

24

48

Leucine

6

9.9

6

16

22

28

48

72

Leucine

7

10.5

6

18

23

28

48

72

Leucine

8

11.1

6

18

23

28

48

72

Leucine

9

11.7

6

24

48

72

78

96

Leucine

10

12.3

6

24

48

72

96

Leucine

12

13.5

6

24

48

72

96

Glycine

6

7.4

1

3

5

7

9

24

Glycine

7

8.1

1

3

5

7

9

24

Glycine

8

8.7

1

3

5

7

9

24

Glycine

9

9.3

1

3

5

7

9

24

Glycine

10

9.9

1

3

5

7

9

24

The 1H NMR data was collected and the percentage of substrate hydrolyzed was
calculated based on the methods developed in the preliminary assays. The results from the
individual assays for each compound were averaged and standard deviation was calculated to
show error (Table 3.3).

76

Table 3.3: Results of Pig Liver Esterase Assays of N-Acylated Amino Acids
Aliquot
1 SD

2 SD

3 SD

4 SD

5 SD

6 SD

N-pentanoyl-L-leucine

0.26 0.105 0.40 0.059 0.49 0.079 0.77 0.045 0.80 0.084 0.87 0.058

N-hexanoyl-L-leucine

0.33 0.011 0.53 0.034 0.58 0.025 0.62 0.083 0.68 0.032 0.76 0.057

N-heptanoyl-L-leucine

0.28 0.151 0.42 0.054 0.51 0.047 0.54 0.015 0.66 0.035 0.73 0.041

N-octanoyl-L-leucine

0.19 0.069 0.33 0.043 0.42 0.044 0.48 0.023 0.54 0.091 0.60 0.136

N-nonanoyl-L-leucine

0.13 0.034 0.32 0.018 0.41 0.029 0.46 0.004 0.49 0.010 0.51 0.047

N-decanoyl-L-leucine

0.18 0.024 0.22 0.026 0.24 0.020 0.29 0.008 0.33 0.022

N-dodecanoyl-L-leucine 0.13 0.022 0.22 0.085 0.21 0.007 0.25 0.016 0.34 0.033
N-hexanoylglycine

0.27 0.008 0.46 0.009 0.56 0.020 0.61 0.012 0.68 0.005 0.91 0.005

N-heptanoylglycine

0.27 0.056 0.39 0.020 0.48 0.013 0.54 0.067 0.61 0.014 0.85 0.022

N-octanoylglycine

0.23 0.015 0.32 0.026 0.39 0.027 0.49 0.005 0.55 0.002 0.77 0.050

N-nonanoylglycine

0.20 0.008 0.28 0.004 0.39 0.056 0.44 0.022 0.58 0.025 0.71 0.010

N-decanoylglycine

0.21 0.037 0.28 0.086 0.46 0.034 0.51 0.009 0.53 0.006 0.54 0.039

Alongside the N-alkyl amino acids, the activity of PLE on the 2,5-diketopiperazine
derivatives was also measured using these optimized assay conditions (Table 3.4).

Table 3.4: Amounts of Substrate and Aliquot Times for Pig Liver Esterase Assay of 2,5Diketopiperazine Derivatives
Compound

Substrate (mg)

Aliquot Times (hours)
1

2

3

4

5

6

N,N’-dipentanoyl-2,5-diketopiperazine

12.1

4

6

10

24

48

72

N,N’-dioctanoyl-2,5-diketopiperazine

15.8

8

24

32

48

72

96

N,N’-didodecanoyl-2,5-diketopiperazine

20.6

8

24

32

48

72

96

The 1H NMR data was collected and the percentage of substrate fully hydrolyzed was
calculated based on the methods developed in the optimized assays. The results from the
individual assays for each compound were averaged and standard deviation was calculated to
show margins of error (Table 3.5).
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Table 3.5: Results of Pig Liver Esterase Assays of 2,5-Diketopiperazine Derivatives
Aliquot
1 SD

2 SD

3 SD

4 SD

5 SD

6 SD

N,N'-dipentanoyl-2,5-diketopiperazine

0.25

0.040

0.38

0.036

0.48

0.035

0.57

0.031

0.68

0.031

0.75

0.061

N,N'-dioctanoyl-2,5-diketopiperazine

0.24

0.050

0.40

0.053

0.48

0.021

0.51

0.003

0.57

0.017

0.61

0.021

N,N'-didodecanoyl-2,5-diketopiperazine

0.12

0.025

0.18

0.026

0.22

0.020

0.26

0.025

0.29

0.026

0.32

0.026

3.3.4 Amano PS Lipase Assay of Ketogenic Compounds
An analogous enzymatic study was carried out to investigate whether the other lipase
selected, Amano PS, is effective at hydrolyzing the target compounds. Below is a general
procedure:
Amano PS lipase (6 mg, >30 units/mg) was dissolved in a 50 mM phosphate buffer
solution at pH 7 (4 mL) and allowed to stir for twenty minutes at 50°C. A sample of Nheptanoylglycine (34) (8.1 mg, 0.043 mmol) and N-octanoyl-L-leucine (19) (11.1 mg, 0.043
mmol) were each dissolved in DMSO (0.2 mL). 1.0 mL of a 50 mM phosphate buffer solution at
pH 7 was added dropwise to each sample while stirring at 360 Hz. The spin was reduced to 120
Hz and the samples were heated to 50°C. The lipase mixture (2 mL, 1.5 mg/mL) was added
dropwise to each sample and the samples were allowed to stir. Aliquots of 0.5 mL were taken at
T=4, 24, and 48 hours. Each aliquot was washed three times with ethyl acetate (2 mL) and the
organic layers were combined and evaporated by rotary evaporation. The crude residue was
taken up in CDCl3 (0.6 mL) for NMR analysis. The 1H NMR spectra were acquired, but did not
indicate the presence of free fatty acid even after 48 hours (Fig. 3.8 & Fig. 3.9). In each case, the
spectra showed signals corresponding to only the starting N-acyl amino acid. To verify that the
enzyme was active, trioctanoylglyceride was used as a positive control (Fig. 3.10). This
compound was completely hydrolyzed by the enzyme within 1 hour.
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Figure 3.8: Amano PS Lipase Assay of N-Heptanoylglycine

Figure 3.9: Amano PS Lipase Assay of N-Octanoyl-L-Leucine
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Figure 3.10: Amano PS Lipase Assay of Trioctanoylglyceride

Because of the chemical similarities between the a hydrogens of the free fatty acid and
the ester, the amount of substrate was measured by the single proton signal of the glycerol
backbone in trioctanoylglyceride. After an hour, no trioctanoylglyceride remained. Based on
these results, further enzyme assays using Amano PS lipase to hydrolyze the other N-acyl amino
acids were not performed.
Amano PS lipase activity on glycerol acetoacetate triester was also measured. After one
hour, no substrate remained under the original conditions. However, due to the high solubility of
glycerol in water and the instability of acetoacetate upon hydrolysis, quantitative 1H NMR
analysis was not possible using this protocol. However, it appears likely that lipase activity on
glycerol acetoacetate triester is high.
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3.4 Analysis of Enzymatic Hydrolysis Assay of Ketogenic Compounds
The results of the PLE assays can be plotted out together for each N-fatty acyl amino acid
(Fig. 3.11 & Fig. 3.12), as a function of time. The plots provide some insight into the relationship
that the type of amino acid and the fatty acid chain length play in enzyme hydrolytic activity
(Table 3.6). It appears that the PLE activity is inversely related to fatty acid chain length in Nacylglycine compounds.

Porcine Liver Esterase Activity on
N-Alkylglycine Compounds
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Figure 3.11: Porcine Liver Esterase Activity on N-Acylglycine Compounds vs. Time
Similarly, it appears that the N-acyl-L-leucine compounds follow a similar pattern (Fig.
3.12). As fatty acid chain length increases, the rate of hydrolysis decreases.
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Porcine Liver Esterase Activity on
N-Acyl-L-Leucine Compounds
Amount of Substrate Hydrolyzed (%)
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Figure 3.12: Porcine Liver Esterase Activity on N-Acyl-L-Leucine Compounds vs. Time

The rate of hydrolysis of 2,5-diketopiperazine derivatives by PLE follows a similar
pattern (Fig. 3.13). This is a measurement of the full hydrolysis of these derivatives to 2,5diketopiperazine. The rate of hydrolysis of a single fatty acid may be different, but was not
measured.
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Amount of Substrate Hydrolyzed (%)

Porcine Liver Esterase Activity on
N,N'-Dialkyl-2,5-diketopiperazine Compounds
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Figure 3.13: Porcine Liver Esterase Activity on N,N’-Dialkyl-2,5-diketopiperazine Compounds
vs. Time

The time at which half of the substrate was hydrolyzed (t1/2) was estimated based on the
data acquired using linear trendlines between the two points nearest to t1/2 (Table 3.6).
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Table 3.6: t1/2Values for Porcine Liver Esterase Activity on Ketogenic Compounds
Derivatized Group

Fatty Acid

Chain Length

t1/2 (hours)

Glycine

Hexanoic Acid

6

3.75

Glycine

Heptanoic Acid

7

5.75

Glycine

Nonanoic Acid

9

6.77

Glycine

Octanoic Acid

8

7.38

Leucine

Pentanoic Acid

5

8.34

2,5-Diketopiperazine

Pentanoic Acid

5

13.17

Leucine

Hexanoic Acid

6

14.61

Glycine

Decanoic Acid

10

16.21

Leucine

Heptanoic Acid

7

22.60

Leucine

Octanoic Acid

8

34.53

2,5-Diketopiperazine

Octanoic Acid

8

42.11

Leucine

Nonanoic Acid

9

88.75

The t1/2 values have a strong inverse relationship with fatty acid chain length within both
the glycine and leucine series. The only exception for this is the t1/2 for N-octanoylglycine,
which is slightly longer than N-nonanoylglycine, but this is most likely due to standard deviation
between samples, as the results for these two compounds were similar.
It is clear that the N-acylglycine compounds are more easily hydrolyzed by porcine liver
esterase than the N-acyl-L-leucine compounds. This could be because the isopropyl side chain
on leucine decreases the binding and catalytic activity of PLE, and the smaller size of glycine
allows it to fit more easily into the active site.
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The two 2,5-diketopiperazine derivatives where a t1/2 was obtained appeared to have the
same relationship between fatty acid chain length and rate of hydrolysis, although at a much
slower rate than the glycine derivatives.

3.5 Compound Stability Across Different pH Levels
While enzymatic hydrolysis is likely the primary process through which the synthesized
compounds would release ketogenic products in the body, it is not the only means through which
this could occur. The stability of select synthesized compounds across a large pH range was
measured to determine if the compounds could generate ketogenic groups without requiring
enzymatic hydrolysis.

3.5.1 Protocol for Measuring pH Stability
Below is a protocol for the pH stability assay for the synthetic compounds, in this case,
for N-hexanoylglycine:
Four different samples of N-hexanoylglycine (33) (7.4 mg, 0.043 mmol) were dissolved
in DMSO (0.4 mL) at room temperature. Buffer solutions at pH = 3, 6, 8, and 10 were added
dropwise (3.0 mL). Samples were covered with parafilm and allowed to sit for 30 days. A 1.0
mL aliquot was collected, washed three times with ethyl acetate (2 mL), and the organic layers
were combined and evaporated by rotary evaporation. The residue was taken up in CDCl3 and
1

H NMR analysis was performed using a 400 MHz NMR spectrometer.
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3.5.2 Preparation of Buffer Solutions
Buffer solutions at pH = 3, 6, 8, and 10 were prepared. A FisherbrandTM accumetTM
AE150 benchtop pH meter was used to measure pH levels. The pH levels of the buffer solutions
were adjusted to the correct values using 0.1 M solutions of hydrochloric acid (HCl) and 0.1 M
solutions of sodium hydroxide (NaOH) before dilution.
A pH = 3 buffer solution was prepared by adding 44.6 mL of a 0.1 M HCl solution to 100
mL of a 0.1 M potassium hydrogen phthalate solution and diluting to 200 mL with DI water.
A pH = 6 buffer solution was prepared by adding 11.2 mL of a 0.1 M NaOH solution to
100 mL of a 0.1 M potassium dihydrogen phosphate solution and diluting to 200 mL with DI
water.
A pH = 8 buffer solution was prepared by adding 93.4 mL of a 0.1 M NaOH solution to
100 mL of a 0.1 M potassium dihydrogen phosphate solution and diluting to 200 mL with DI
water.
A pH = 10 buffer solution was prepared by adding 21.4 mL of a 0.1 M NaOH solution to
100 mL of a 0.05 M sodium bicarbonate solution and diluting to 200 mL with DI water.

3.5.3 Results of pH Stability Assays
Solubility issues limited the range of pH values that could be studied for different
compounds. These attempts were made by dissolving the compound in DMSO, then slowly
adding the aqueous buffer to the solution. In some cases, the test compound immediately
precipitated or coagulated onto the glass. For instance, N,N’-dipentanoyl-2,5-diketopiperazine
(36) was insoluble in both acidic and basic conditions, and thus the rate of hydrolysis could not
be measured. N-Hexanoylglycine (33) and N-octanoyl-L-leucine (18) were both insoluble under
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acidic conditions where hydrolysis would be likely to occur. Both appeared to be completely
stable in basic conditions, as no measurable hydrolysis had occurred after 30 days. On the other
hand, t-butyl (Z)-(4-methoxy-4-oxobut-2-en-2-yl)-L-leucinate (39), the enamine formed between
methyl acetoacetate and L-leucine t-butyl ester, and glycerol acetoacetate triester (41), were both
soluble across the full range of pH values tested (pH 3-10). For the enamine (39), partial
hydrolysis occurred very slowly at pH = 3 but not at any of the other pH values examined. Figure
3.14 illustrates the proton NMR spectra for the samples at the different pH´s, after 30 days of
exposure.

Figure 3.14: 30-Day pH Stability Assay for t-Butyl (Z)-(4-methoxy-4-oxobut-2-en-2-yl)-LLeucinate (39)
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Based on the integration values of the isopropyl groups in the starting material and the Lleucine t-butyl ester generated upon hydrolysis, approximately 70% of the starting material was
hydrolyzed after 30 days at pH 3.
For glycerol acetoacetate triester (41), partial hydrolysis under basic conditions occurred.
Figure 3.15 shows the proton NMR spectra for the samples at the different pH´s, after 30 days of
exposure.

Figure 3.15: 30-Day pH Stability Assay for Glycerol Acetoacetate Triester (41)

Partial hydrolysis of glycerol acetoacetate triester was beginning to occur under basic
conditions but was very slow. Both of these compounds appear to be almost completely resistant
to hydrolysis from pH 3 to pH 6, and partially hydrolyzed in basic media (pH 8 and 10).
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3.6 Digestive Enzyme Assays of Ketogenic Compounds
While PLE and Amano PS lipase were used based on their suspected activity against the
synthesized compounds, it was important to also measure the activity of common, readily
available digestive enzymes. Preliminary assays using trypsin and pepsin were done to
determine whether they might hydrolyze the compounds synthesized.
Trypsin, a serine protease found in the small intestine, helps hydrolyze peptide bonds. It
is most active between pH 8 and 9. Pepsin, an endopeptidase found in the stomach, is also
involved in protein digestion. It is most active between pH 1 and 2. However, due to the low
solubility of the synthetic ketogenic compounds at low pH levels, the assay was done at pH = 7.
The protocol used to measure the activity of PLE against ketogenic compounds was
adapted to measure the activity of both trypsin and pepsin on synthetic ketogenic compounds.

3.6.1 Pepsin Assay of Ketogenic Compounds
Below is a protocol for the pepsin hydrolysis assay for the synthetic compounds, in this
case, for N-hexanoylglycine:
Pepsin from porcine gastric mucosa (3 mg, 250 units/mg) was dissolved in a 50 mM
phosphate buffer solution at pH = 8 (3 mL) and allowed to stir for thirty minutes at 25°C. Nhexanoylglycine (33) (7.4 mg, 0.043 mmol) was dissolved in DMSO (0.4 mL). 2.0 mL of a 50
mM phosphate buffer solution at pH 8 was added dropwise to the sample while stirring at 360
Hz. The spin was reduced to 120 Hz and the pepsin solution (1 mL, 1 mg/mL) was added
dropwise and the sample was allowed to stir. Aliquots were taken at T = 4, 24, and 48 hours.
Aliquots were washed three times with ethyl acetate (2 mL) and the organic layers were
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combined and evaporated by rotary evaporation. The residue was taken up in CDCl3 and 1H
NMR analysis was performed using a 400 MHz NMR spectrometer.

3.6.2 Trypsin Assay of Ketogenic Compounds
Below is a protocol for the trypsin hydrolysis assay for the synthetic compounds, in this
case, for N-hexanoylglycine:
Trypsin from bovine pancreas (3 mg, 7,500 BAEE units/mg) was dissolved in a 50 mM
phosphate buffer solution at pH=7 (3 mL) and allowed to stir for thirty minutes at 25°C. Nhexanoylglycine (33) (7.4 mg, 0.043 mmol) was dissolved in DMSO (0.4 mL). 2.0 mL of a 50
mM phosphate buffer solution at pH 7 was added dropwise to each sample while stirring at 360
Hz. The spin was reduced to 120 Hz and the trypsin solution (1 mL, 1 mg/mL) was added
dropwise to each sample and the samples were allowed to stir. Aliquots were taken at T = 4, 24,
and 48 hours. Aliquots were washed three times with ethyl acetate (2 mL) and the organic layers
were combined and evaporated by rotary evaporation. The residue was taken up in CDCl3 and
1

H NMR analysis was performed using a 400 MHz NMR spectrometer.

3.6.3 Results of Digestive Enzyme Assays
Activity of trypsin and pepsin were measured against N-hexanoylglycine (33), Noctanoyl-L-leucine (18), t-butyl (Z)-(4-methoxy-4-oxobut-2-en-2-yl)-L-leucinate (39), and
glycerol acetoacetate triester (41). For all four of these compounds tested, no hydrolysis
occurred within 48 hours. It is unlikely that trypsin or pepsin are active against the ketogenic
compounds synthesized.
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3.7 Conclusions
Preliminary analysis of the hydrolytic stability of the synthesized compounds against four
representative hydrolase proteins and at different pH values was carried out. A lack of reliance
on enzymatic hydrolysis would make these compounds more appealing as ketogenic compounds,
for quick release of the ketone body-forming units. On the other hand, resistance to acid or basepromoted hydrolysis would endow the compounds with the necessity to undergo enzymatic
hydrolysis in the body. These initial explorations suggest that the compounds are relatively stable
to trypsin and pepsin under the experimental conditions, while the pH studies were largely
restricted by the inherently low water solubility of the fatty acyl compounds. However, some
meaningful results were obtained for porcine liver esterase and Amano PS lipase, particular for
the N-acyl glycine and N-acyl leucine derivatives, which show a clear structure-activity profile.
Analyzing first the stability of these acylated compounds across a broad pH range (pH 310) showed that the compounds are stable towards hydrolytic cleavage of the acyl moiety. The
enamines and the 2,5-diketopiperazine derivatives appear to be more stable to the basic media,
but more sensitive to hydrolysis under mildly acidic conditions. Conversely, the glycerol
acetoacetate triester slowly hydrolyzes in basic media (pH 8 to 10), albeit not at an appreciable
rate under the conditions tested (DMSO and aqueous buffer).
Using porcine liver esterase, the enzymatic hydrolysis of N-acyl amino acids and 2,5diketopiperazine derivatives was shown across a wide spectrum of fatty acid chain lengths for
two representative amino acids (glycine and leucine). The rates at which half of the substrate is
hydrolyzed was calculated. It is likely that these fatty acids would be cleaved using similar
esterases in the human digestive tract and in other organs of the body to generate fatty acids. The
other indication is that one can predictably control the rate of release of the ketogenic component
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(the fatty acid), and the kinetics of ketogenic response, through selection of the amino acid
carrier. This is worthy of further study using other amino acids and perhaps the D-antipode of
leucine, which may be drastically different in terms of enzymatic recognition and hydrolysis.
Using Amano PS lipase, the enzymatic hydrolysis of glycerol acetoacetate triester was
shown. While detailed information about the rate of hydrolysis was not acquired, it does
increase the likelihood it would provide a positive effect on ketogenicity in the human body.
The use of these simple assays shows that these synthetic compounds could be
metabolized to generate ketogenic products in the body. The described methodology allows for
the testing of panels of compounds in order to verify ketogenic potential. These assays,
meanwhile, do not confirm that the compounds are ketogenic per se, but merely are capable of
producing compounds that are known to undergo ketone body formation in human cells. In the
next chapter, additional biological evaluations are done using an animal model to measure in
vivo ketogenicity.
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CHAPTER IV

IN VIVO TESTING OF NOVEL KETOGENIC COMPOUNDS

4.1 Introduction
The use of ketogenic food substances and dietary supplements to induce and maintain
ketosis is a recent area of focus in the field of research surrounding the ketogenic diet. Several
synthetic ketogenic compounds have been developed and tested in rodent models and humans
and shown to raise blood ketone body concentrations to levels indicative of ketosis. Mice and
rodent models provide an excellent way to systematically examine the effects of these ketogenic
components at the biochemical and organism level while maintaining a normal diet regimen
under experimentally-controlled conditions.

4.2 Background
As mentioned previously, research using animals to study the effects of synthetic
ketogenic compounds first began in the 1970s and 1980s (Fig. 4.1). Interest in alternatives to
dietary fats that could be given to patients intravenously led to the synthesis of several possible
candidates whose effectiveness was measured in different animals.
The monoacetoacetate esters of glycerol were synthesized in 1979 as a way to deliver
calories in the form of both glucose and ketone bodies intravenously.129 Male Holtzman rats
were given either the monoacetoacetyl glyceride mixture or glucose intravenously alongside a
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low-calorie diet for 7 days, after which the concentration of glucose, pyruvate, acetoacetate, and
R-b-hydroxybutyrate in the blood was measured. Similarly, mixtures of (±)-1,3-butanediol
acetoacetate diester and the monoesters were synthesized to deliver calories as ketone bodies and
given to male Yorkshire-Landrace pigs.90,91 Animals were fasted overnight and given the
ketogenic compound intravenously over 3 hours. Blood samples were taken at various times
over 5 hours and the concentrations of glucose, acetoacetate, R-b-hydroxybutyrate, S-bhydroxybutyrate, pyruvate, and lactate were taken. An increase in ketone body concentrations
were observed in the results of both these experiments, but the emphasis of the testing was
placed on the tolerance of the compounds and their effects on the health of the animals.

Figure 4.1: Early Synthetic Ketogenic Compounds
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With increased interest in the ketogenic diet in recent years, animal studies have been
performed using a variety of natural and synthetic ketogenic compounds with hyperketonemia as
the focus. The first synthetic ketogenic compound to induce ketosis in an animal model without
fasting and while on a normal diet was (R)-3-hydroxybutyl (R)-3-hydroxybutyrate, the enzymecatalyzed synthesis of which was published by Veech in 2010 (Fig. 4.2).95

Figure 4.2: Published Synthesis of (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate

Wistar rats were shown to tolerate the monoester over 28 days, although the research that
showed elevated ketone body concentrations in their blood was unpublished.96 However, (R)-3hydroxybutyl (R)-3-hydroxybutyrate was administered to humans at different dosages as a meal
replacement beverage with 25% of the calories coming from the ketogenic compound. This
beverage was given at different doses (140-714 mg ketogenic compound / kg body weight) and
supplemented with a commercially available meal replacement drink (Ensure®). R-bHydroxybutyrate and acetoacetate concentrations in the blood were elevated in the first five
hours in a dose-dependent manner.97 More recent studies have shown these results were
consistent across daily administration of the compound over 28 days.98
The capabilities of a broad spectrum of ketogenic supplements to induce ketosis without
dietary restrictions was shown in Sprague-Dawley rats by D’Agostino in 2016.6 Medium-chain
triglyceride (MCT) oil, a 1:1 mixture of MCT oil and racemic sodium and potassium b-
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hydroxybutyrate salts, racemic sodium and potassium b-hydroxybutyrate salts alone, (±)-1,3butanediol, and (±)-1,3-butanediol acetoacetate diester were all tested.
Ketogenic supplements were administered via intragastric gavage daily for 28 days, and
every 7 days blood samples were periodically taken for up to 12 hours afterwards. MCT oil, the
MCT oil and b-hydroxybutyrate salt mixture, (±)-1,3-butanediol, and (±)-1,3-butanediol
acetoacetate diester all showed elevated concentrations of (R)-b-hydroxybutyrate within the first
few hours compared to a control group given no supplement. MCT oil, the MCT oil and bhydroxybutyrate salt mixture, and (±)-1,3-butanediol acetoacetate diester all caused a decrease in
blood glucose concentration in the rats compared to a control group given no supplement.
Recently, the use of a 1:1 mixture of MCT oil and racemic sodium and potassium bhydroxybutyrate salts and (±)-1,3-butanediol acetoacetate diester were shown to increase (R)-bhydroxybutyrate concentrations and decrease blood glucose concentrations in mice models to
similar levels to those found in rats.5,6

4.3 Testing of Synthetic Compounds for Ketogenicity in Mice
In order to determine the effectiveness of novel synthetic compounds to induce ketosis,
animal testing was performed on two of the compounds prepared in chapter 2. Mice were chosen
as an appropriate model for this initial study based on the reduced amount of compound required
for testing compared to rats or other larger animals. All data was acquired using a commercially
available Precision Xtra® blood glucose and ketone monitoring system.
Two compounds were tested, the enamine formed from t-butyl L-leucine and methyl
acetoacetate (39) and glycerol acetoacetate triester (41) (Fig 4.3).
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Figure 4.3: Synthetic Compounds Tested for Ketogenicity

The enamine was chosen based on its sensitivity to acidic environments like the stomach,
while the glycerol acetoacetate triester was chosen based on its sensitivity to hydrolysis by lipase
and its similarity to other acetoacetate esters that have been shown to be ketogenic.

4.3.1 Experimental Procedure for Testing for Ketogenicity in Mice
These experiments were performed in the research laboratory of Professor Dominic
D’Agostino under the auspices of IACUC protocol IS00005524. VM/Dk mice between 2 and 5
months of age were allowed to acclimate to the testing facility for one week before being
separated into four weight matched groups and housed individually. Three days later, the tails of
the mice were clipped under isoflurane anesthesia to allow for blood sampling during testing.
Two days later, testing was performed.
Food was removed from cages for two hours, but water was left available. Baseline
concentrations of levels of (R)-b-hydroxybutyrate and blood glucose concentrations were
measured by taking a drop of blood from the clipped tail using the test strips used with the
Precision Xtra® blood glucose and ketone monitoring system. The test compound was
administered via oral gavage at different concentrations based on the group, with one group
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receiving only water as a control. Five mice were used in each test group. Blood ketone and
glucose concentrations were measured at T= 0.5, 1, 2, 3, 5, and 24 hours.

4.3.2 Discussion of Results
The data obtained from the blood samples taken from the treated mice were tabulated.
The enamine (39) produced no statistically relevant increase in (R)-b-hydroxybutyrate
concentration or decrease in blood glucose concentration, compared to the control (Tables 4.1
and 4.2), but glycerol acetoacetate triester produced a meaningful increase in both (Tables 4.3
and 4.4).

Table 4.1: Concentration of (R)-b-Hydroxybutyrate (mM) over Time in Mice Treated with
Enamine (39) versus the Control
Control (0 mg sample / g body weight)
Time

Mouse 1

Mouse 2

Mouse 3

Mouse 4

Mouse 5

Average

St. Dev.

0

0.8

0.7

0.7

0.7

0.7

0.7

0.04

0.5

0.7

0.8

0.4

0.4

0.6

0.6

0.18

1

0.9

0.6

0.4

0.5

0.6

0.6

0.19

2

0.6

0.7

0.3

0.4

0.6

0.5

0.16

3

0.8

0.4

0.5

0.4

0.5

0.5

0.16

2.5 mg sample / g body weight
Time

Mouse 1

Mouse 2

Mouse 3

Mouse 4

Mouse 5

Average

St. Dev.

0

0.9

0.7

0.6

0.9

0.8

0.8

0.13

0.5

0.9

0.7

0.6

0.7

0.9

0.8

0.13

1

0.7

0.8

0.9

0.7

1

0.8

0.13

2

0.6

0.6

0.9

0.7

0.8

0.7

0.13
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Table 4.1 (Continued)
3

0.6

0.7

0.5

0.6

0.7

0.6

0.08

5.0 mg sample / g body weight
Time

Mouse 1

Mouse 2

Mouse 3

Mouse 4

Mouse 5

Average

St. Dev.

0

0.7

0.7

0.8

0.7

0.6

0.7

0.07

0.5

0.7

0.6

0.5

0.6

0.6

0.6

0.07

1

0.6

0.6

0.7

0.7

0.5

0.6

0.08

2

0.6

0.9

1.1

0.9

0.6

0.8

0.22

3

0.6

0.6

1.1

0.9

0.6

0.8

0.23

Mouse 4

Mouse 5

Average

St. Dev.

10 mg sample / g body weight
Time

Mouse 1

Mouse 2

Mouse 3

0

0.6

0.7

0.6

0.8

0.6

0.7

0.09

0.5

0.7

0.6

0.4

0.6

0.6

0.6

0.11

1

0.4

0.6

0.6

0.6

0.6

0.6

0.09

2

0.7

0.8

0.6

0.6

0.9

0.7

0.13

3

0.4

0.6

0.8

0.6

0.6

0.6

0.14

Table 4.2: Blood Glucose Concentration over Time in Mice Treated with Enamine (39) versus
the Control
Control (0 mg sample / g body weight)
Time

Mouse 1

Mouse 2

Mouse 3

Mouse 4

Mouse 5

Average

St. Dev.

0

109

156

148

170

149

146

22.7

0.5

114

158

200

174

149

159

31.7

1

192

173

207

206

215

199

16.5

2

183

233

229

199

184

206

24.1
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Table 4.2 (Continued)
3

158

137

134

140

211

156

32.1

2.5 mg sample / g body weight
Time

Mouse 1

Mouse 2

Mouse 3

Mouse 4

Mouse 5

Average

St. Dev.

0

103

137

137

149

138

133

17.4

0.5

131

165

168

193

130

157

26.9

1

189

209

195

193

163

190

16.8

2

146

157

84

181

172

148

38.2

3

163

126

147

136

106

136

21.5

5.0 mg sample / g body weight
Time

Mouse 1

Mouse 2

Mouse 3

Mouse 4

Mouse 5

Average

St. Dev.

0

110

161

170

115

130

137

27.0

0.5

121

186

138

168

153

153

25.3

1

86

158

105

142

134

125

29.1

2

143

199

61

72

178

131

62.0

3

123

159

57

83

158

116

45.4

10 mg sample / g body weight
Time

Mouse 1

Mouse 2

Mouse 3

Mouse 4

Mouse 5

Average

St. Dev.

0

143

127

126

128

147

134

10.0

0.5

165

114

184

212

140

163

38.0

1

200

112

160

185

114

154

40.2

2

149

61

107

191

60

114

56.8

3

142

135

173

163

130

149

18.6
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A plot of the average concentration of (R)-b-hydroxybutyrate for each group at each time
point shows the effects the enamine (39) had on the ketone body concentration in the mice (Fig.
4.4). While it appears at first that there may be a small perturbation on (R)-b-hydroxybutyrate
concentration in the blood, a large standard deviation in each data set and a lack of any
relationship between dosage and effect make it likely that this compound is not affecting (R)-bhydroxybutyrate concentration in a statistically meaningful way.

(R)-b-hydroxybutyrate Concentration (mM)

Effects of Methyl Acetoacetate t-Butyl
Leucine Ester Enamine on
Concentration of (R)-b-hydroxybutyrate in Blood of
VM/Dk Mice over Time
1.2
1.0
0.8
0 mg / g (control)

0.6

2.5 mg / g
5.0 mg / g

0.4

10 mg / g

0.2
0.0
0

0.5

1

1.5

2

2.5

3

3.5

Time (hours)

Figure 4.4: Concentration of (R)-b-Hydroxybutyrate in Blood vs. Time for Enamine (39)

Similarly, a plot of the average concentration of glucose for each group at each time point
shows the effects the enamine (39) had on the blood glucose levels in the mice (Fig. 4.5). There
appears to be some effect on blood glucose levels, but again, the large standard deviation
101

combined with a lack of a relationship between sample dose and effect, it is difficult to argue the
compound had an effect on blood glucose concentration.

Effects of Methyl Acetoacetate t-Butyl Leucine Ester
Enamine on Blood Glucose Concentration in
VM/Dk Mice over Time
Blood Glucose Concentration (mg/dL)

250

200

150

0 mg / g (control)
2.5 mg / g

100

5.0 mg / g
10 mg / g

50

0
0

0.5

1

1.5

2

2.5

3

3.5

Time (hours)

Figure 4.5: Concentration of Blood Glucose vs. Time for Enamine (39)

Table 4.3: Concentration of (R)-b-Hydroxybutyrate (mM) over Time in Mice Treated with
Glycerol Triester (41) versus the Control
Control (0 mg sample / g body weight)
Time

Mouse 1

Mouse 2

Mouse 3

Mouse 4

Mouse 5

Average

St. Dev.

0

0.7

0.8

0.8

0.7

0.7

0.74

0.05

0.5

0.5

0.6

0.5

0.7

0.5

0.56

0.09

1

0.7

0.9

0.6

0.7

0.7

0.72

0.11

2

0.6

0.8

0.8

0.5

0.6

0.66

0.13
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Table 4.3 (Continued)
3

0.6

0.7

0.6

0.6

0.7

0.64

0.05

4

0.8

0.7

0.7

0.4

0.6

0.64

0.15

5

0.6

0.4

0.5

0.4

0.6

0.50

0.10

24

0.4

0.5

0.7

0.8

0.5

0.58

0.16

2.2 mg sample / g body weight
Time

Mouse 6

Mouse 7

Mouse 8

Mouse 9

Mouse 10

Average

St. Dev.

0

1.0

1.2

0.9

0.7

0.9

0.94

0.18

0.5

0.9

1.1

1.2

0.8

1.0

1.00

0.16

1

1.3

1.4

1.4

1.6

1.2

1.38

0.15

2

1.2

1.3

1.1

1.8

1.1

1.30

0.29

3

0.7

1.1

0.8

1.6

0.9

1.02

0.36

4

0.8

1.3

0.7

0.8

0.8

0.88

0.24

5

0.7

0.9

0.9

0.6

0.7

0.76

0.13

24

0.6

0.9

0.8

0.4

0.8

0.70

0.20

4.4 mg sample / g body weight
Time

Mouse 11

Mouse 12

Mouse 13

Mouse 14

Mouse 15

Average

St. Dev.

0

0.7

0.8

0.8

0.7

0.7

0.74

0.05

0.5

1.2

1.6

0.8

0.8

1.3

1.14

0.34

1

1.7

1.2

1.7

0.8

0.9

1.26

0.43

2

2.0

0.9

1.6

1.9

1.4

1.56

0.44

3

2.2

1.1

1.8

2.0

1.6

1.74

0.42

4

2.0

1.1

1.8

1.9

1.7

1.70

0.35

5

0.8

0.8

1.7

1.0

1.8

1.22

0.49

24

0.5

0.5

0.6

0.6

0.6

0.56

0.05

6.6 mg sample / g body weight
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Table 4.3 (Continued)
Time

Mouse 16

Mouse 17

Mouse 18

Mouse 19

Mouse 20

Average

St. Dev.

0

0.8

0.7

0.6

0.8

0.7

0.72

0.08

0.5

0.7

1.3

0.9

2.3

0.9

1.22

0.64

1

1.3

1.7

1.2

2.1

1.2

1.50

0.39

2

2.1

2.2

2.1

2.0

2.4

2.16

0.15

3

2.2

3.2

2.3

1.9

2.6

2.44

0.49

4

2.4

2.6

2.4

2.0

2.6

2.40

0.24

5

2.4

2.2

2.3

1.9

2.4

2.24

0.21

24

0.4

0.6

0.4

0.5

0.4

0.46

0.09

Table 4.4: Blood Glucose Concentration over Time in Mice with Glycerol Triester (41) versus
the Control
Control (0 mg sample / g body weight)
Time

Mouse 1

Mouse 2

Mouse 3

Mouse 4

Mouse 5

Average

St. Dev.

0

164

137

155

137

153

149.2

11.88

0.5

176

188

140

193

165

172.4

21.13

1

195

196

203

200

205

199.8

4.32

2

200

183

214

238

183

203.6

23.20

3

180

164

194

214

223

195.0

24.15

4

166

177

190

207

183

184.6

15.31

5

183

138

202

203

178

180.8

26.40

24

167

130

151

178

133

151.8

20.90

2.2 mg sample / g body weight
Time

Mouse 6

Mouse 7

Mouse 8

Mouse 9

Mouse 10

Average

St. Dev.

0

127

129

121

96

126

119.8

13.63

104

Table 4.4 (Continued)
0.5

162

109

164

156

163

150.8

23.57

1

154

91

172

85

150

130.4

39.64

2

150

88

175

64

140

123.4

45.90

3

164

107

178

57

127

126.6

48.14

4

166

179

179

91

165

156.0

36.96

5

150

183

143

161

141

155.6

17.20

24

132

154

146

134

145

142.2

9.12

4.4 mg sample / g body weight
Time

Mouse 11

Mouse 12

Mouse 13

Mouse 14

Mouse 15

Average

St. Dev.

0

109

151

155

135

124

134.8

19.06

0.5

123

156

136

174

144

146.6

19.46

1

130

156

93

142

140

132.2

23.79

2

60

152

49

48

23

66.4

49.73

3

22

136

54

31

50

58.6

45.24

4

36

175

33

30

25

59.8

64.53

5

178

175

43

130

21

109.4

73.58

24

148

153

113

174

140

145.6

22.14

6.6 mg sample / g body weight
Time

Mouse 16

Mouse 17

Mouse 18

Mouse 19

Mouse 20

Average

St. Dev.

0

160

171

163

110

177

156.2

26.68

0.5

175

133

182

155

163

161.6

19.10

1

130

145

147

68

164

130.8

37.12

2

66

66

25

68

51

55.2

18.21

3

44

21

21

62

53

40.2

18.65

4

37

25

41

43

32

35.6

7.27
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Table 4.4 (Continued)
5

35

28

25

91

34

42.6

27.37

24

148

148

133

154

136

143.8

8.90

A plot of the average concentration of (R)-b-hydroxybutyrate at each time point shows
the effect of glycerol acetoacetate triester on ketone body concentration in mice (Fig. 4.6).

Effects of Glycerol Acetoacetate Triester on
Concentration of (R)-b-hydroxybutyrate in Blood of
VM/Dk Mice over Time

Concentration of (R)- -hydroxybutyrate
in Blood (mM)

3.00

2.50

2.00
0 mg/g (control)

1.50

2.2 mg/g
4.4 mg/g

1.00

6.6 mg/g

0.50

0.00
0
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10

15

20

25

Time (Hours)

Figure 4.6: Concentration of (R)-b-Hydroxybutyrate in Blood vs. Time for Glycerol
Acetoacetate Triester (41)

There is a dose-dependent effect on (R)-b-hydroxybutyrate that appears to peak near 3
hours after administration of the test compound. These results are in agreement with those
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reported previously for a similar study using a 10 mg/g dose of 1:1 mixture of MCT oil and
racemic sodium and potassium b-hydroxybutyrate salts in Sprague-Dawley rats, wherein the
maximum concentration of (R)-b-hydroxybutyrate reached was approximately 2.5 mM, similar
to the average concentration that was observed in this study after 3 hours in the 6.6 mg/g group
of mice.5,147
The average blood glucose concentration for each group at each time point was also
graphed against time to show the effect of glycerol acetoacetate triester on blood glucose levels
in mice (Fig. 4.7).

Effects of Glycerol Acetoacetate Triester on
Blood Glucose Concentration of VM/Dk Mice over Time

Blood Glucose Concentration (mg/dL)

250.0

200.0

150.0
0 mg/g (control)
2.2 mg/g
100.0

4.4 mg/g
6.6 mg/g

50.0

0.0
0

5

10

15

20

25

Time (Hours)

Figure 4.7: Concentration of Blood Glucose vs. Time for Glycerol Acetoacetate Triester (41)

Similar to the effects on (R)-b-hydroxybutyrate concentrations in the blood, glycerol
acetoacetate triester markedly decreased blood glucose concentrations in a dose-dependent
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manner. The maximum anti-glycemic effect of the treatment was observed for the 6.6 mg/g
group at the 4 hour mark after administration, with the blood glucose concentration dropping to
about 42.6 mg/dl, compared to 180 mg/dL for the control mice. The same method in SpragueDawley rats using 10 mg/g of a 1:1 mixture of MCT oil and racemic sodium and potassium bhydroxybutyrate salts caused a decrease in blood glucose concentration to approximately 80
mg/dL versus approximately 120 mg/dL in the control.6

4.3.3 Other Observations of Mice during Testing
There were no issues administering the compound to the mice via gavage. The mice
became more lethargic throughout the day, but there did not appear to be a difference in behavior
between the different groups. The lethargy is possibly due to a lack of food instead of the
glycerol acetoacetate triester. Other than lethargy, no animals showed any other adverse effects
to the treatment.

4.4 Discussion of Glycerol Acetoacetate Triester as a Ketogenic Compound
The effect that glycerol acetoacetate triester had on both elevating (R)-b-hydroxybutyrate
and lowering glucose blood concentrations in mice is extremely promising. (R)-bHydroxybutyrate concentrations were elevated at all concentrations examined in this study. The
largest dose, 6.6 mg of sample per gram of body weight, showed a drastic increase in (R)-bhydroxybutyrate, well into ketosis, that was maintained for several hours. It is important to note
that the analysis done is selective for (R)-b-hydroxybutyrate and does not measure acetoacetate
concentration. Since glycerol acetoacetate triester should generate three equivalents of
acetoacetic acid, it is likely if acetoacetate was measured, an earlier increase in ketone body
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concentration would be observed and a prolonged period of time with elevated ketone body
levels would be observed. Further analysis of the effects of this compound on animal models is
likely required.
Similarly, the decrease in blood glucose concentration within two hours of compound
administration was very strong and was maintained for several hours. The largest dose lowered
the average blood glucose concentration of mice in that group to 42.6 mg/dL, well into the range
of hypoglycemia and nearing a dangerous level.8 The glucose concentration began to rise back to
the normal level within a few hours. However, there were no observable effects on behavior
between groups and all mice remained awake through the entire experiment.

4.5 Conclusions
The results of animal testing on two possible ketogenic compounds synthesized in our lab
revealed positive results for one and justify the continued research into novel synthetic ketogenic
compounds. Glycerol acetoacetate triester showed an increase in (R)-b-hydroxybutyrate
concentration in the blood and a decrease in blood glucose levels that is indicative of ketosis and
similar to other synthetic ketogenic compounds.
This preliminary research into glycerol acetoacetate triester as a novel ketogenic
compound demonstrates that it could be an effective method for inducing ketosis in place of
other compounds or foods. It showed a stronger effect on (R)-b-hydroxybutyrate concentration
than (±)-1,3-butanediol acetoacetate diester and produced similar effects to the 1:1 mixture of
MCT oil and sodium and potassium b-hydroxybutyrate salts, although at even smaller doses.
The effect glycerol acetoacetate triester has on blood glucose concentration appears to be
stronger than that of other synthetic ketogenic compounds. It is likely due to the sharp increase
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of ketone body concentration in the body as glycerol acetoacetate triester is hydrolyzed to
generate three equivalents of acetoacetic acid in addition to one equivalent of 1,3-butanediol.
Further studies into the effects this compound has on total ketone body concentration are needed
to elucidate how this affects glucose concentration in the blood.
Glycerol acetoacetate triester appears to be a new and effective synthetic ketogenic
compound that can be used to carry out further research on the ketogenic diet and its
physiological effects. The initial results are promising and justifies additional exploration by
synthetic chemists to create new ketogenic compounds to better address the needs of both
researchers and consumers of the ketogenic diet.
The syntheses laid out in Chapter 2 that included N-acyl amino acids, 2,5diketopiperazine derivatives, and the glycerol acetoacetate triester illustrate the broad range of
possibilities for this new field. The use of enzymatic assays to determine if synthetic compounds
should be further studied in animal models could allow for the testing of large panels of synthetic
ketogenic compound candidates without the use of costly animal testing. Lastly, the evidence for
glycerol acetoacetate triester as a novel synthetic ketogenic compound justifies further studies
not just for this compound, but for other acetoacetate esters as well.
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CHAPTER V

MATERIALS AND METHODS

5.1 Introduction
All reagents were purchased from either Sigma-Aldrich Chemical Company, Fisher
Scientific Company, Combi-Blocks Inc., or Oakwood Chemical Company. All solvents were
purchased from Fisher Scientific Company. Thin layer chromatography (TLC) was carried out
using Merck plates with a fluorescent indicator (SiO2-60, F-254). Flash chromatography
purification was performed using Dynamic Adsorbents Inc. flash chromatography silica gel (3263 µm). NMR analysis was performed using a Varian Inova 400 MHz spectrometer, Bruker Neo
400 MHz spectrometer, and a Bruker Neo 600 MHz spectrometer.

5.2 Synthesis of Ketogenic Peptides

5.2.1 Synthesis of Boc-Leu-Leu-OtBu (1)
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Generation of Boc-Leu-Leu-OtBu (1): Boc-Leu-OH•H2O (1.86 g, 8.0 mmol), H-Leu-OtBu•HCl
(1.79 g, 8.0 mmol) and N,N-diisopropylethylamine (DIPEA) (1.39 mL, 2.4 mmol) were
dissolved in 10 mL of methylene chloride and stirred for 10 minutes. N-(3Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC) (2.30 g, 12.0 mmol) was
added, the reaction vessel was capped, and allowed to stir for 22 hours. The reaction mixture
was washed with 1N HCl and the solvent was removed by rotary evaporation. TLC in (1:3 ethyl
acetate to hexane) showed a UV-fluorescent spot at Rf = 0.83. Flash column chromatography
using silica gel gave 2.05 g of 1 as a white solid in 64% yield. The product was used without
further purification for the Boc-deprotection in the next step. TLC (1:3 ethyl acetate to hexane,
Rf = 0.83). 1H NMR (400 MHz, Chloroform-d) δ 4.95 – 4.74 (m, 1H), 4.47 (td, J = 8.7, 5.2 Hz,
1H), 1.61 (ddd, J = 21.1, 7.8, 5.4 Hz, 4H), 1.55 – 1.47 (m, 2H), 1.45 (s, 9H), 1.43 (s, 9H), 0.98 –
0.88 (m, 12H).

5.2.2 Synthesis of Dileucine (2)

Generation of Dileucine (2): Crude protected peptide 1 (2.05 g, 5.1 mmol) in a 50 mL roundbottom flask was put under the inert conditions of a nitrogen atmosphere and 10 mL of a 4.0 M
HCl solution in dioxane was added via syringe. The reaction was allowed to stir for 24 hours at
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room temperature before the solvent was removed by rotary evaporation. The solid product was
washed with 80 mL of chloroform and dried by rotary evaporation to give 0.918 g of 2 as an offwhite solid in 41% yield. 1H NMR (400 MHz, Deuterium Oxide) δ 4.42 (dd, J = 9.0, 4.3 Hz,
1H), 4.04 (t, J = 7.1 Hz, 1H), 2.00 – 1.50 (m, 6H), 0.97 (d, J = 6.0 Hz, 6H), 0.92 (d, J = 6.1 Hz,
6H).

5.2.3 Synthesis of Fmoc-Leu-Leu-OtBu (3)

Generation of Fmoc-Leu-Leu-OtBu (3): Fmoc-Leu-OH (2.90 g, 8.2 mmol), H-Leu-OtBu•HCl
(1.83 g, 8.2 mmol), and DIPEA (0.42 mL, 2.4 mmol) were added to a 50 mL round-bottom flask,
dissolved in 10 mL of methylene chloride, and allowed to stir for 10 minutes. EDC (1.86 g, 9.7
mmol) was added, the reaction vessel was capped and allowed to stir at room temperature for 16
hours. The reaction mixture was washed with 1 partition of 1N HCl, dried over anhydrous
sodium sulfate, and filtered. The solvent was removed by rotary evaporation to give an amber
oil. TLC (1:4 ethyl acetate:hexane) showed two UV-fluorescent spots at Rf = 0, 0.47. The
product was purified via flash column chromatography on silica gel using 1:4 ethyl
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acetate:hexane to give 2.265 g of 3 as a yellow oil in 53% yield. 1H NMR (400 MHz,
Chloroform-d) δ 7.76 (dd, J = 7.6, 3.1 Hz, 2H), 7.58 (d, J = 7.5 Hz, 2H), 7.40 (dd, J = 7.5, 3.3
Hz, 2H), 7.35 – 7.29 (m, 2H), 4.54 – 4.26 (m, 3H), 4.22 (dd, J = 7.2, 3.0 Hz, 2H), 1.77 (s, 4H),
1.45 (s, 9H), 1.19 (t, J = 7.3 Hz, 2H), 1.02 – 0.86 (m, 12H).

5.2.4 Synthesis of H-Leu-Leu-OtBu (4)

Generation of H-Leu-Leu-OtBu (4): Fmoc-Leu-Leu-OtBu (3) (2.00 g, 4.3 mmol) was dissolved
in 30 mL of acetonitrile. 10 mL of diethylamine (DEA) was added and the mixture was allowed
to stir at room temperature for 90 minutes. The solvent was removed by rotary evaporation until
a yellow oil remained. The oil was dissolved in 120 mL chloroform and the solvent was
removed by rotary evaporation. NMR spectroscopy still showed the presence of DEA, so the
product was washed with 75 mL of chloroform and the solvent as removed by rotary evaporation
to give 0.48 g of 4 as an off-white solid in 39% yield. 1H NMR (400 MHz, Chloroform-d) δ 4.48
(td, J = 8.9, 5.0 Hz, 1H), 3.41 (dd, J = 9.9, 3.6 Hz, 1H), 1.72 – 1.60 (m, 3H), 1.54 – 1.50 (m, 1H),
1.46 (s, 9H), 1.41 – 1.28 (m, 2H), 1.10 – 0.76 (m, 12H).
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5.2.5 Synthesis of Boc-Leu-Leu-Leu-OtBu (5)

Generation of Boc-Leu-Leu-Leu-OtBu (6): H-Leu-Leu-OtBu (0.48 g, 1.7 mmol) and Boc-LeuOH•H2O (0.42 g, 1.7 mmol) were dissolved in 50 mL of methylene chloride along with DIPEA
(0.42 mL, 4.8 mmol) and allowed to stir at room temperature for 10 minutes. EDC (0.46 g, 2.4
mmol) was added, the reaction vessel was capped and allowed to stir for 16 hours. The reaction
mixture was rinsed with two partitions of 50 mL of 1N HCl, dried over anhydrous sodium
sulfate, filtered, and the solvent was evaporated by rotary evaporation. The resulting crude
product was purified by flash column chromatography using 1:3 ethyl acetate:hexane to afford
the product 5 as an oily residue. The product was used crude and not weighed before
deprotection. 1H NMR (400 MHz, Chloroform-d) δ 4.85 (d, J = 8.3 Hz, 1H), 4.62 – 4.33 (m,
2H), 1.73 – 1.59 (m, 6H), 1.50 – 1.37 (m, 21H), 1.10 – 0.77 (m, 18H).
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5.2.6 Synthesis of Trileucine (6)

Generation of Trileucine (6): Unweighed crude protected peptide 5 in a 50mL round-bottom
flask was put under the inert conditions of a nitrogen atmosphere and 10 mL of a 4.0M HCl
solution in dioxane was added via syringe. The reaction was allowed to stir for 24 hours at room
temperature before the solvent was removed by rotary evaporation. The solid product was
washed with 80 mL of chloroform and dried by rotary evaporation to give 0.918 g of 6 as an offwhite solid. 1H NMR (400 MHz, Deuterium Oxide) δ 4.52 – 4.38 (m, 2H), 4.02 (t, J = 7.2 Hz,
1H), 1.79 – 1.56 (m, 8H), 1.06 – 0.84 (m, 18H).
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5.3 Synthesis of N-Acyl Amino Acids

5.3.1 Procedure for Coupling of Saturated Fatty Acids to L-Leucine t-Butyl Ester

Synthesis of O-tert-butyl N-propanoyl-L-leucine (7): L-Leucine tert-butyl ester hydrochloride
(0.67 g, 3.0 mmol) and 4-dimethylaminopyridine (0.48 g, 3.9 mmol) were added to 10 mL of
dichloromethane and stirred until dissolved. Propionic acid (0.22 mL, 3.0 mmol) was added and
allowed to stir for 10 minutes. EDC (0.56 g, 3.9 mmol) was added and the reaction vessel was
capped. The mixture was allowed to stir for 16 hours at room temperature. The mixture was
diluted with dichloromethane to 25 mL. The mixture was washed with one 25 mL partition each
of a 10% w/v citric acid solution, water, saturated sodium bicarbonate solution, and saturated
brine solution. The organic layer was dried over anhydrous sodium sulfate, filtered, and the
organic solvent was removed by rotary evaporation to give 0.6912 g of 7 as a clear oil in 95%
yield. 1H NMR (400 MHz, Chloroform-d) δ 5.84 (d, J = 8.4 Hz, 1H), 4.53 (td, J = 8.5, 5.3 Hz,
1H), 2.24 (q, J = 7.6 Hz, 2H), 1.71 – 1.54 (m, 2H), 1.51 – 1.47 (m, 1H), 1.46 (s, 9H), 1.16 (t, J =
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7.6 Hz, 3H), 0.95 (d, J = 1.6 Hz, 3H), 0.93 (d, J = 1.8 Hz, 3H).

13

C NMR (101 MHz,

Chloroform-d) δ 173.41, 172.61, 81.91, 51.14, 42.16, 29.62, 28.01, 24.97, 22.82, 22.22, 9.73.

O-tert-Butyl N-Pentanoyl-L-leucinate (8): Clear oil, 82% yield. 1H NMR (400 MHz,
Chloroform-d) δ 5.92 (d, J = 8.4 Hz, 1H), 4.52 (td, J = 8.6, 5.3 Hz, 1H), 2.25 – 2.15 (m, 2H),
1.72 – 1.52 (m, 4H), 1.52 – 1.46 (m, 1H), 1.43 (s, 9H), 1.34 (hept, J = 7.3 Hz, 2H), 0.92 (d, J =
6.4 Hz, 6H), 0.89 (t, J = 7.1 Hz, 3H).

13

C NMR (101 MHz, Chloroform-d) δ 172.89, 172.60,

81.87, 51.14, 42.05, 36.36, 27.99, 27.74, 24.96, 22.82, 22.36, 22.15, 13.80.

O-tert-Butyl N-Hexanoyl-L-leucinate (9): Clear oil, 68% yield1H NMR (400 MHz,
Chloroform-d) δ 5.90 (d, J = 8.4 Hz, 1H), 4.52 (td, J = 8.6, 5.3 Hz, 1H), 2.23 – 2.14 (m, 2H),
1.69 – 1.53 (m, 4H), 1.49 (dd, J = 6.7, 1.9 Hz, 1H), 1.45 (s, 9H), 1.36 – 1.20 (m, 4H), 0.94 (d, J
= 1.1 Hz, 3H), 0.92 (d, J = 1.3 Hz, 3H), 0.87 (t, J = 6.8 Hz, 3H).

13

C NMR (101 MHz,

Chloroform-d) δ 172.88, 172.60, 81.87, 51.14, 42.08, 36.62, 31.41, 27.99, 25.34, 24.96, 22.82,
22.39, 22.16, 13.96.

O-tert-Butyl N-Heptanoyl-L-leucinate (10): Clear oil, 83% yield. 1H NMR (400 MHz,
Chloroform-d) δ 5.91 (d, J = 8.4 Hz, 1H), 4.52 (td, J = 8.6, 5.3 Hz, 1H), 2.23 – 2.14 (m, 2H),
1.70 – 1.43 (m, 4H), 1.51 – 1.46 (m, 1H), 1.44 (s, 9H), 1.34 – 1.22 (m, 6H), 0.93 (d, J = 1.3 Hz,
3H), 0.92 (d, J = 1.4 Hz, 3H), 0.85 (t, J = 6.7 Hz, 3H).

13

C NMR (101 MHz, Chloroform-d) δ

172.88, 172.61, 81.86, 51.12, 42.08, 36.66, 31.52, 28.91, 27.99, 25.63, 24.96, 22.82, 22.51,
22.15, 14.04.
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O-tert-Butyl N-Octanoyl-L-leucinate (11): Clear oil, 91% yield. 1H NMR (400 MHz,
Chloroform-d) δ 5.87 (d, J = 8.4 Hz, 1H), 4.52 (td, J = 8.6, 5.3 Hz, 1H), 2.19 (dd, J = 8.5, 7.0
Hz, 2H), 1.68 – 1.56 (m, 4H), 1.52 – 1.47 (m, 1H), 1.46 (s, 9H), 1.34 – 1.22 (m, 8H), 0.94 (d, J =
1.4 Hz, 3H), 0.92 (d, J = 1.5 Hz, 3H), 0.86 (t, J = 6.2 Hz, 3H).

13

C NMR (101 MHz,

Chloroform-d) δ 172.87, 172.60, 81.87, 51.13, 42.10, 36.68, 31.70, 29.20, 29.00, 28.00, 25.66,
24.96, 22.82, 22.60, 22.17, 14.09.

O-tert-Butyl N-Nonanoyl-L-leucinate (12): Clear oil, 70% yield.

1

H NMR (400 MHz,

Chloroform-d) δ 5.89 (d, J = 8.5 Hz, 1H), 4.52 (td, J = 8.6, 5.3 Hz, 1H), 2.19 (dd, J = 8.4, 6.8 Hz,
2H), 1.70 – 1.53 (m, 4H), 1.51 – 1.46 (m, 1H), 1.45 (s, 9H), 1.37 – 1.15 (m, 10H), 0.94 (d, J = 1.3
Hz, 3H), 0.92 (d, J = 1.4 Hz, 3H), 0.86 (t, J = 6.8 Hz, 3H).

13

C NMR (101 MHz, Chloroform-d) δ

172.94, 172.58, 81.88, 51.14, 42.07, 36.65, 31.81, 29.30, 29.24, 29.17, 27.99, 25.67, 24.96, 22.82,
22.66, 22.15, 14.11.

O-tert-Butyl N-Decanoyl-L-leucinate (13): Clear oil, 79% yield.

1

H NMR (400 MHz,

Chloroform-d) δ 5.89 (d, J = 8.5 Hz, 1H), 4.52 (td, J = 8.6, 5.3 Hz, 1H), 2.19 (dd, J = 8.5, 7.0 Hz,
2H), 1.70 – 1.54 (m, 4H), 1.52 – 1.47 (m, 1H), 1.45 (s, 9H), 1.36 – 1.17 (m, 12H), 0.94 (d, J = 1.2
Hz, 3H), 0.92 (d, J = 1.3 Hz, 3H), 0.86 (t, J = 6.7 Hz, 3H).

13

C NMR (101 MHz, Chloroform-d) δ

172.85, 172.62, 81.86, 51.11, 42.10, 36.69, 31.88, 29.46, 29.35, 29.27, 29.25, 27.99, 25.67, 24.96,
22.82, 22.68, 22.16, 14.13.

O-tert-Butyl N-Dodecanoyl-L-leucinate (14): Yellow oil, 84% yield.

1

H NMR (400 MHz,

Chloroform-d) δ 5.89 (d, J = 8.4 Hz, 1H), 4.65 – 4.41 (m, 1H), 2.19 (dd, J = 8.4, 6.8 Hz, 2H), 1.70
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– 1.53 (m, 4H), 1.51 – 1.47 (m, 1H), 1.45 (s, 9H), 1.31 – 1.20 (m, 16H), 0.94 (d, J = 1.2 Hz, 3H),
0.92 (d, J = 1.3 Hz, 3H), 0.86 (t, J = 6.7 Hz, 3H).

13

C NMR (101 MHz, Chloroform-d) δ 172.86,

172.62, 81.86, 51.12, 42.09, 36.69, 31.92, 29.62, 29.51, 29.35, 29.25, 27.99, 25.67, 24.96, 22.82,
22.70, 22.16, 14.14.

5.3.2 Procedure for Deprotecting t-Butyl N-Fatty Acyl Leucinates

Generation of N-Pentanoyl-L-leucine (15): Compound 8 (0.6712 g, 2.47 mmol) was dissolved in
dry dichloromethane (2 mL). The reaction vial was put under a nitrogen atmosphere and
trifluoroacetic acid (2 mL) was added via syringe. The reaction was allowed to stir at room
temperature for 1 hour. Solvent and volatiles were removed by rotary evaporation at 70°C and the
resulting oil was dried under a flow of air. The resulting solid was dissolved in dichloromethane
(10 mL), washed with 1 10 mL partition each of water and saturated brine solution, dried over
anhydrous sodium sulfate, and filtered. The organic solvent was removed by rotary evaporation
to give 0.3558 g of 15 as an off-white solid in 67% yield. 1H NMR (400 MHz, Chloroform-d) δ
5.97 (d, J = 8.0 Hz, 1H), 4.61 (td, J = 8.6, 4.6 Hz, 1H), 2.25 (t, J = 7.6 Hz, 2H), 1.80 – 1.67 (m,
2H), 1.65 – 1.51 (m, 3H), 1.35 (h, J = 7.4 Hz, 2H), 0.96 (d, J = 3.8 Hz, 3H), 0.94 (d, J = 3.6 Hz,
120

3H), 0.91 (t, J = 7.3 Hz, 3H).

13

C NMR (101 MHz, Chloroform-d) δ 176.40, 174.19, 50.87, 41.06,

36.24, 27.66, 24.90, 22.86, 22.32, 21.87, 13.80.

N-Hexanoyl-L-leucine (16): White solid, 73% yield. 1H NMR (400 MHz, Chloroform-d) δ 5.91
(d, J = 7.9 Hz, 1H), 4.60 (td, J = 8.4, 4.7 Hz, 1H), 2.24 (t, J = 7.6 Hz, 2H), 1.80 – 1.66 (m, 2H),
1.67 – 1.52 (m, 3H), 1.38 – 1.24 (m, 4H), 0.96 (d, J = 3.8 Hz, 3H), 0.95 (d, J = 3.7 Hz, 3H), 0.89
(t, J = 6.9 Hz, 3H).

13

C NMR (101 MHz, Chloroform-d) δ 176.18, 174.17, 50.88, 41.00, 36.47,

31.34, 25.27, 24.89, 22.85, 22.38, 21.86, 13.96.

N-Heptanoyl-L-leucine (17): Pink solid, 77% yield. 1H NMR (400 MHz, Chloroform-d) δ 5.93
(d, J = 7.9 Hz, 1H), 4.63 (td, J = 8.3, 4.8 Hz, 1H), 2.28 (t, J = 7.6 Hz, 2H), 1.83 – 1.70 (m, 2H),
1.70 – 1.54 (m, 3H), 1.43 – 1.20 (m, 6H), 0.99 (d, J = 4.3 Hz, 3H), 0.97 (d, J = 4.2 Hz, 3H), 0.91
(t, J = 6.9 Hz, 3H).

13

C NMR (101 MHz, Chloroform-d) δ 175.81, 174.55, 50.92, 40.90, 36.46,

31.46, 28.82, 25.56, 24.89, 22.83, 22.50, 21.83, 14.04.

N-Octanoyl-L-leucine (18): Off-white solid, 29% yield. 1H NMR (400 MHz, Chloroform-d) δ
5.80 (d, J = 7.8 Hz, 1H), 4.71 – 4.42 (m, 1H), 2.24 (t, J = 7.6 Hz, 2H), 1.80 – 1.69 (m, 2H), 1.69 –
1.52 (m, 3H), 1.38 – 1.19 (m, 8H), 0.97 (d, J = 4.9 Hz, 3H), 0.95 (d, J = 4.6 Hz, 3H), 0.87 (t, J =
7.0 Hz, 3H).

13

C NMR (101 MHz, Chloroform-d) δ 175.08, 174.30, 50.93, 40.76, 36.49, 31.68,

29.14, 28.98, 25.56, 24.87, 22.85, 22.62, 21.85, 14.11.

N-Nonanoyl-L-leucine (19): Off-white solid, 87% yield. 1H NMR (400 MHz, Chloroform-d) δ
5.85 (d, J = 7.9 Hz, 1H), 4.60 (td, J = 8.3, 4.8 Hz, 1H), 2.24 (t, J = 7.6 Hz, 2H), 1.82 – 1.68 (m,
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2H), 1.68 – 1.54 (m, 3H), 1.42 – 1.15 (m, 10H), 0.96 (d, J = 4.3 Hz, 3H), 0.95 (d, J = 4.0 Hz, 3H),
0.87 (t, J = 6.7 Hz, 3H).

13

C NMR (101 MHz, Chloroform-d) δ 175.70, 174.24, 50.90, 40.91,

36.50, 31.81, 29.27, 29.19, 29.16, 25.58, 24.88, 22.85, 22.66, 21.85, 14.13.

N-Decanoyl-L-leucine (20): Off-white solid, 86% yield. 1H NMR (400 MHz, Chloroform-d) δ
5.92 (d, J = 8.0 Hz, 1H), 4.60 (td, J = 8.6, 4.7 Hz, 1H), 2.24 (t, J = 7.6 Hz, 2H), 1.80 – 1.67 (m,
2H), 1.66 – 1.52 (m, 3H), 1.38 – 1.15 (m, 12H), 0.96 (d, J = 3.9 Hz, 3H), 0.95 (d, J = 3.7 Hz, 3H),
0.87 (t, J = 6.7 Hz, 3H).

13

C NMR (101 MHz, Chloroform-d) δ 176.16, 174.21, 50.89, 41.01,

36.50, 31.89, 29.46, 29.33, 29.28, 29.20, 25.60, 24.90, 22.86, 22.70, 21.86, 14.15.

N-Dodecanoyl-L-leucine (21): Tan solid, 90% yield. 1H NMR (400 MHz, Chloroform-d) δ 5.81
(d, J = 7.7 Hz, 1H), 4.66 – 4.42 (m, 1H), 2.25 (t, J = 7.6 Hz, 3H), 1.84 – 1.69 (m, 2H), 1.68 – 1.52
(m, 3H), 1.36 – 1.19 (m, 16H), 0.97 (d, J = 5.0 Hz, 3H), 0.95 (d, J = 4.9 Hz, 3H), 0.88 (t, J = 6.7
Hz, 3H).

13

C NMR (101 MHz, Chloroform-d) δ 175.68, 50.95, 40.72, 36.47, 31.93, 29.62, 29.48,

29.36, 29.31, 29.18, 25.57, 24.86, 22.84, 22.71, 21.85, 14.16.

1

H NMR (400 MHz, Chloroform-d) δ 5.81 (d, J = 7.7 Hz, 1H), 4.66 – 4.42 (m, 1H), 2.25 (t, J =

7.6 Hz, 3H), 1.84 – 1.69 (m, 2H), 1.68 – 1.52 (m, 3H), 1.36 – 1.19 (m, 16H), 0.97 (d, J = 5.0 Hz,
3H), 0.95 (d, J = 4.9 Hz, 3H), 0.88 (t, J = 6.7 Hz, 3H).
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5.3.3 Procedure for Coupling of Saturated Fatty Acids to Glycine t-Butyl Ester

Synthesis of O-tert-butyl propionylglycinate (22): Glycine tert-butyl ester hydrochloride (0.50
g, 3.0 mmol) and 4-dimethylaminopyridine (0.48 g, 3.9 mmol) were added to 10 mL of
dichloromethane and stirred until dissolved. Propionic acid (0.22 mL, 3.0 mmol) was added and
allowed to stir for 10 minutes. EDC (0.56 g, 3.9 mmol) was added and the reaction vessel was
capped. The reaction was allowed to stir for 16 hours at room temperature. The reaction
mixture was diluted with dichloromethane to 25 mL. The reaction mixture was washed with one
25 mL partition each of a 10% w/v citric acid solution, water, saturated sodium bicarbonate
solution, and saturated brine solution. The organic layer was dried over anhydrous sodium
sulfate, filtered, and the organic solvent was removed by rotary evaporation to give 0.507 g of 23
as a yellow crystalline solid in 90% yield. 1H NMR (600 MHz, Chloroform-d) δ 6.02 (s, 1H),
3.92 (d, J = 4.8 Hz, 2H), 2.25 (q, J = 7.6 Hz, 2H), 1.46 (s, 9H), 1.16 (t, J = 7.6 Hz, 3H).

13

C

NMR (151 MHz, Chloroform-d) δ 173.82, 169.31, 82.30, 42.01, 29.39, 28.03, 9.66.

O-tert-Butyl Pentanoylglycinate (23): Clear oil, 65% yield. 1H NMR (600 MHz, Chloroformd) δ 5.94 (s, 1H), 3.93 (d, J = 4.9 Hz, 2H), 2.26 – 2.20 (m, 2H), 1.62 (tt, J = 8.9, 6.8 Hz, 2H),
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13

1.47 (s, 9H), 1.39 – 1.32 (m, 2H), 0.91 (t, J = 7.4 Hz, 3H).

C NMR (151 MHz, Chloroform-d)

δ 173.15, 169.32, 82.32, 42.01, 36.20, 28.05, 27.67, 22.38, 13.78.

O-tert-Butyl Hexanoylglycinate (24): Clear oil, 88% yield. 1H NMR (600 MHz, Chloroform-d)
δ 5.99 (s, 1H), 3.92 (d, J = 4.9 Hz, 2H), 2.32 – 2.15 (m, 2H), 1.63 (tt, J = 7.6, 6.2 Hz, 2H), 1.39 –
1.19 (m, 4H), 0.87 (t, J = 6.9 Hz, 3H). 13C NMR (151 MHz, Chloroform-d) δ 173.20, 169.31,
82.28, 42.00, 36.42, 31.43, 28.03, 25.27, 22.38, 13.91.

O-tert-Butyl Heptanoylglycinate (25): Yellow oil, 67% yield. 1H NMR (400 MHz,
Chloroform-d) δ 5.96 (s, 1H), 3.93 (d, J = 4.9 Hz, 2H), 2.36 – 2.06 (m, 2H), 1.72 – 1.53 (m, 2H),
13

1.46 (s, 9H), 1.38 – 1.20 (m, 6H), 0.87 (t, J = 7.0 Hz, 3H).

C NMR (101 MHz, Chloroform-d)

δ 173.24, 169.34, 82.34, 42.01, 36.50, 31.53, 28.96, 28.05, 25.57, 22.51, 14.06.

O-tert-Butyl Octanoylglycinate (26): Yellow oil, 85% yield. 1H NMR (400 MHz, Chloroformd) δ 5.96 (t, J = 5.1 Hz, 1H), 3.93 (d, J = 5.0 Hz, 2H), 2.37 – 2.07 (m, 2H), 1.63 (t, J = 7.4 Hz,
2H), 1.46 (s, 9H), 1.37 – 1.13 (m, 8H), 0.86 (t, J = 6.9 Hz, 3H).

13

C NMR (101 MHz,

Chloroform-d) δ 173.21, 169.36, 82.32, 42.00, 36.51, 31.67, 29.24, 29.01, 28.04, 25.61, 22.62,
14.09.

O-tert-Butyl Nonanoylglycinate (27): Clear oil, 85% yield. 1H NMR (400 MHz, Chloroform-d)
δ 5.97 (s, 1H), 3.92 (d, J = 4.9 Hz, 2H), 2.21 (t, J = 7.7 Hz, 2H), 1.62 (dd, J = 9.1, 5.7 Hz, 2H),
1.46 (s, 9H), 1.35 – 1.15 (m, 10H), 0.86 (t, J = 7.2 Hz, 3H).

13

C NMR (101 MHz, Chloroform-d)

δ 173.24, 169.34, 82.33, 42.00, 36.50, 31.82, 29.31, 29.29, 29.15, 28.05, 25.61, 22.66, 14.12.
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O-tert-Butyl Decanoylglycinate (28): Clear oil, 72% yield. 1H NMR (400 MHz, Chloroform-d)
δ 5.96 (t, J = 5.1 Hz, 1H), 3.93 (d, J = 4.9 Hz, 2H), 2.34 – 2.12 (m, 2H), 1.62 (q, J = 7.3 Hz, 2H),
1.46 (s, 9H), 1.36 – 1.17 (m, 12H), 0.86 (t, J = 6.7 Hz, 3H).

13

C NMR (101 MHz, Chloroform-d)

δ 173.23, 169.35, 82.35, 42.01, 36.52, 31.88, 29.44, 29.35, 29.29, 28.05, 25.62, 22.69, 14.14.

O-tert-Butyl Dodecanoylglycinate (29): White crystalline solid, 57% yield. 1H NMR (400
MHz, Chloroform-d) δ 5.92 (s, 1H), 3.94 (d, J = 4.9 Hz, 2H), 2.22 (t, J = 7.7 Hz, 2H), 1.62 (q, J
= 7.4 Hz, 3H), 1.47 (s, 9H), 1.37 – 1.13 (m, 16H), 0.87 (t, J = 6.7 Hz, 3H).

13

C NMR (101 MHz,

Chloroform-d) δ 173.19, 169.37, 82.36, 42.01, 36.54, 31.93, 29.63, 29.49, 29.36, 29.30, 28.06,
25.62, 22.71, 14.16.

5.3.4 Procedure for Deprotecting t-Butyl N-Fatty Acyl Glycinates

Generation of N-Hexanoylglycine (30): Compound 24 (0.608 g, 2.65 mmol) was dissolved in dry
dichloromethane (2 mL).

The reaction vial was put under a nitrogen atmosphere and

trifluoroacetic acid (2 mL) was added via syringe. The reaction was allowed to stir at room
temperature for 1 hour. Solvent and volatiles were removed by rotary evaporation at 70°C and the

125

resulting oil was dried under a flow of air. The resulting solid was dissolved in dichloromethane
(10 mL), washed with 1 partition each of water and a saturated brine solution, dried over anhydrous
sodium sulfate, and filtered. The organic solvent was removed by rotary evaporation to give 0.061
g of 30 as a white solid in 13% yield. 1H NMR (400 MHz, Chloroform-d) δ 6.12 (s, 1H), 4.08 (d,
J = 5.1 Hz, 2H), 2.27 (t, J = 7.7 Hz, 2H), 1.72 – 1.55 (m, 2H), 1.42 – 1.15 (m, 4H), 0.89 (t, 3H).
3

C NMR (101 MHz, Chloroform-d) δ 174.51, 172.47, 41.56, 36.28, 31.34, 25.21, 22.38, 13.95.

N-Heptanoylglycine (31): Off-white solid, 25% yield. 1H NMR (400 MHz, Chloroform-d) δ 6.17
(d, J = 5.4 Hz, 1H), 4.08 (d, J = 5.1 Hz, 2H), 2.27 (t, J = 7.7 Hz, 2H), 1.64 (p, J = 7.6 Hz, 2H),
1.44 – 1.14 (m, 6H), 1.01 – 0.73 (t, J = 7.0 Hz, 3H).

13

C NMR (101 MHz, Chloroform-d) δ 174.60,

172.62, 41.56, 36.32, 31.49, 28.86, 25.50, 22.50, 14.06.

N-Octanoylglycine (32): White solid, 17% yield. 1H NMR (400 MHz, Chloroform-d) δ 6.03 (s,
1H), 4.09 (d, J = 5.1 Hz, 2H), 2.26 (t, J = 7.6 Hz, 2H), 1.65 (t, J = 7.3 Hz, 2H), 1.46 – 1.08 (m,
8H), 0.89 (t, J = 7.0 Hz, 3H).

13

C NMR (101 MHz, Chloroform-d) δ 174.35, 171.80, 41.52, 36.34,

31.67, 29.17, 28.99, 25.53, 22.63, 14.11.

N-Nonanoylglycine (33): White solid, 4.6% yield. 1H NMR (400 MHz, Chloroform-d) δ 6.06 (s,
1H), 4.08 (d, J = 5.3 Hz, 2H), 2.26 (t, J = 7.7 Hz, 2H), 1.63 (t, J = 7.3 Hz, 2H), 1.40 – 1.20 (m,
10H), 0.87 (t, J = 6.4 Hz, 3H).

13

C NMR (101 MHz, Chloroform-d) δ 172.11, 171.43, 41.52,

36.35, 34.22, 31.82, 29.22, 25.53, 22.67, 17.67, 14.13.
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N-Decanoylglycine (34): Tan solid, 72% yield. 1H NMR (400 MHz, Chloroform-d) δ 6.04 (s,
1H), 4.09 (d, J = 5.2 Hz, 2H), 2.26 (t, J = 7.6 Hz, 2H), 1.64 (t, J = 7.3 Hz, 2H), 1.44 – 1.10 (m,
12H), 0.87 (t, J = 6.7 Hz, 3H).

13

C NMR (101 MHz, Chloroform-d) δ 174.36, 171.99, 41.52,

36.34, 31.88, 29.43, 29.33, 29.28, 29.21, 25.52, 22.69, 14.15.

N-Dodecanoylglycine (35): White solid, 9.0% yield. 1H NMR (400 MHz, Chloroform-d) δ 6.01
(s, 1H), 4.09 (d, J = 5.1 Hz, 2H), 2.26 (t, J = 7.5 Hz, 2H), 1.63 (t, J = 7.2 Hz, 2H), 1.39 – 1.16 (m,
16H), 0.88 (t, J = 6.8 Hz, 3H).

13

C NMR (101 MHz, Chloroform-d) δ 175.06, 174.30, 50.93,

40.77, 36.49, 31.68, 29.14, 28.98, 25.56, 24.87, 22.85, 22.61, 21.85, 14.10.

5.4 Procedure for Coupling Fatty Acids to 2,5-Diketopiperazine

Generation of N,N’-Dipentanoyl-2,5-diketopiperazine (36): 2,5-Diketopiperazine (0.186 g, 1.11
mmol) and 4-dimethylaminopyridine (0.353 g, 2.89 mmol) were dissolved in 5 mL
dichloromethane. Pentanoic acid (0.24 mL, 2.22 mmol) was added and allowed to stir for 10
minutes. EDC (0.554, 2.89 mmol) was added, the reaction vessel was capped, and the mixture
was allowed to stir for 16 hours at room temperature. The reaction mixture was diluted with
dichloromethane to 25 mL. The reaction mixture was washed with one 25 mL partition each of a
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10% w/v citric acid solution, water, saturated sodium bicarbonate solution, and saturated brine
solution. The organic layer was dried over anhydrous sodium sulfate, filtered, and the organic
solvent was removed by rotary evaporation to give 0.063 g of 36 as a crystalline solid in 20.1%
yield. 1H NMR (400 MHz, Chloroform-d) δ 4.58 (s, 4H), 2.94 (t, J = 7.4 Hz, 4H), 1.73 – 1.57 (m,
4H), 1.48 – 1.29 (m, 4H), 0.93 (t, J = 7.3 Hz, 6H). 13C NMR (101 MHz, Chloroform-d) δ 174.13,
165.92, 47.48, 38.63, 26.41, 22.21, 13.88.

N,N’-Dioctanoyl-2,5-diketopiperazine (37): White crystalline solid, 38% yield. 1H NMR (600
MHz, Chloroform-d) δ 4.57 (s, 4H), 2.93 (t, J = 7.4 Hz, 4H), 1.73 – 1.58 (m, 4H), 1.37 – 1.22 (m,
16H), 0.87 (t, J = 6.8 Hz, 6H).

13

C NMR (151 MHz, Chloroform-d) δ 174.12, 165.90, 47.48, 38.86,

31.66, 29.02, 24.34, 22.60, 14.07.

N,N’-Didodecanoyl-2,5-diketopiperazine (38): Off-white crystalline solid, 24.6% yield. 1H
NMR (400 MHz, Chloroform-d) δ 4.58 (s, 2H), 2.93 (t, J = 7.4 Hz, 2H), 2.77 (d, J = 6.6 Hz, 1H),
2.34 (t, J = 7.5 Hz, 2H), 2.17 (s, 1H), 1.64 (h, J = 7.8 Hz, 4H), 1.40 – 1.06 (m, 32H), 0.88 (t, J =
6.8 Hz, 6H).

13

C NMR (101 MHz, Chloroform-d) δ 174.16, 165.93, 47.47, 43.08, 38.91, 33.81,

31.93, 29.63, 29.36, 29.09, 24.73, 24.34, 22.72, 14.17.

128

5.5 Procedure for Synthesis of Methyl Acetoacetate and L-Leucine Ester Enamines

Generation of t-Butyl (Z)-(4-methoxy-4-oxobut-2-en-2-yl)-L-leucinate (39): L-Leucine tertbutyl ester (3.48 g, 18.6 mmol) was added to methyl acetoacetate (2.00 mL, 18.6 mmol) in a 20
mL scintillation vial. The mixture was allowed to stir at 50°C for 16 hours before it was allowed
to cool to room temperature to give 5.18 g of 39 as a clear oil in 97.6% yield. 1H NMR (400
MHz, Chloroform-d) δ 8.63 (s, 1H), 4.52 (s, 1H), 3.95 (td, J = 8.6, 6.6 Hz, 1H), 3.62 (s, 3H),
1.87 (s, 3H), 1.76 (tt, J = 14.6, 7.3 Hz, 1H), 1.63 (td, J = 8.8, 6.7 Hz, 2H), 1.48 (s, 9H), 0.96 (d, J
= 6.6 Hz, 3H), 0.91 (d, J = 6.5 Hz, 3H).

13

C NMR (101 MHz, Chloroform-d) δ 172.02, 170.63,

160.72, 83.92, 81.75, 55.24, 50.04, 41.96, 27.95, 24.68, 22.85, 21.84, 19.50.

Benzyl (Z)-(4-methoxy-4-oxobut-2-en-2-yl)-L-Leucinate (40): Clear oil, 96.4% yield. 1H
NMR (400 MHz, Chloroform-d) δ 8.71 (d, J = 9.1 Hz, 1H), 7.40 – 7.28 (m, 5H), 5.16 (s, 2H),
4.53 (s, 1H), 4.12 (dt, J = 9.1, 7.1 Hz, 1H), 3.63 (s, 3H), 1.80 – 1.72 (m, 1H), 1.68 (t, J = 7.0 Hz,
2H), 0.94 (d, J = 6.3 Hz, 3H), 0.90 (d, J = 6.3 Hz, 3H).

13

C NMR (101 MHz, Chloroform-d) δ

172.63, 170.68, 160.50, 135.49, 128.59, 128.40, 128.19, 84.38, 66.93, 54.58, 50.10, 41.83, 24.61,
22.82, 21.72, 19.48.
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5.6 Procedure for Synthesis of Glycerol Acetoacetate Triester (41)

Generation of Glycerol Acetoacetate Triester (41): Glycerol (9.814 g, 107 mmol) was added to
t-butyl acetoacetate (52.6 mL, 321 mmol) in a 150 mL round-bottom flask. The flask was equipped
with a Dean-Stark trap and a condenser and heated to 150°C. After 3 hours, 30 mL of t-butanol
had been distilled and the reaction was removed from heat and allowed to cool to room temperature
to give 36.470 g of 42 as a slightly yellowed oil in 99.9% yield. 1H NMR (400 MHz, Chloroformd) δ 5.38 – 5.28 (m, 1H), 4.37 (d, J = 4.2 Hz, 1H), 4.34 (d, J = 4.2 Hz, 1H), 4.28 (d, J = 6.2 Hz,
1H), 4.25 (d, J = 6.2 Hz, 1H), 3.43 (s, 6H), 2.17 (s, 9H).
200.28, 166.61, 69.49, 62.46, 49.52, 30.17.
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13

C NMR (101 MHz, Chloroform-d) δ

CHAPTER VI

1

H AND 13C NMR SPECTRA

Figure 6.1: 1H NMR (400 MHz, Chloroform-d) (1)
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Figure 6.2: 1H NMR (400 MHz, Deuterium Oxide) (2)

Figure 6.3: 1H NMR (400 MHz, Chloroform-d) (3)
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Figure 6.4: 1H NMR (400 MHz, Chloroform-d) (4)

Figure 6.5: 1H NMR (400 MHz, Chloroform-d) (5)
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Figure 6.6: 1H NMR (400 MHz, Deuterium Oxide) (6)

Figure 6.7: 1H NMR (400 MHz, Chloroform-d) (7)
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Figure 6.8: 13C NMR (101 MHz, Chloroform-d) (7)

Figure 6.9: 1H NMR (400 MHz, Chloroform-d) (8)
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Figure 6.10: 13C NMR (101 MHz, Chloroform-d) (8)

Figure 6.11: 1H NMR (400 MHz, Chloroform-d) (9)
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Figure 6.12: 13C NMR (101 MHz, Chloroform-d) (9)

Figure 6.13: 1H NMR (400 MHz, Chloroform-d) (10)
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Figure 6.14: 13C NMR (101 MHz, Chloroform-d) (10)

Figure 6.15: 1H NMR (400 MHz, Chloroform-d) (11)
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Figure 6.16: 13C NMR (101 MHz, Chloroform-d) (11)

Figure 6.17: 1H NMR (400 MHz, Chloroform-d) (12)
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Figure 6.18: 13C NMR (101 MHz, Chloroform-d) (12)

Figure 6.19: 1H NMR (400 MHz, Chloroform-d) (13)
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Figure 6.20: 13C NMR (101 MHz, Chloroform-d) (13)

Figure 6.21: 1H NMR (400 MHz, Chloroform-d) (14)
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Figure 6.22: 13C NMR (101 MHz, Chloroform-d) (14)

Figure 6.23: 1H NMR (400 MHz, Chloroform-d) (15)
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Figure 6.24: 13C NMR (101 MHz, Chloroform-d) (15)

Figure 6.25: 1H NMR (400 MHz, Chloroform-d) (16)
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Figure 6.26: 13C NMR (101 MHz, Chloroform-d) (16)

Figure 6.27: 1H NMR (400 MHz, Chloroform-d) (17)
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Figure 6.28: 13C NMR (101 MHz, Chloroform-d) (17)

Figure 6.29: 1H NMR (400 MHz, Chloroform-d) (18)
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Figure 6.30: 13C NMR (101 MHz, Chloroform-d) (18)

Figure 6.31: 1H NMR (400 MHz, Chloroform-d) (19)
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Figure 6.32: 13C NMR (101 MHz, Chloroform-d) (19)

Figure 6.33: 1H NMR (400 MHz, Chloroform-d) (20)
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Figure 6.34: 13C NMR (101 MHz, Chloroform-d) (20)

Figure 6.35: 1H NMR (400 MHz, Chloroform-d) (21)

148

Figure 6.36: 13C NMR (101 MHz, Chloroform-d) (21)

Figure 6.37: 1H NMR (600 MHz, Chloroform-d) (22)
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Figure 6.38: 13C NMR (151 MHz, Chloroform-d) (22)

Figure 6.39: 1H NMR (600 MHz, Chloroform-d) (23)
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Figure 6.40: 13C NMR (151 MHz, Chloroform-d) (23)

Figure 6.41: 1H NMR (600 MHz, Chloroform-d) (24)
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Figure 6.42: 13C NMR (151 MHz, Chloroform-d) (24)

Figure 6.43: 1H NMR (400 MHz, Chloroform-d) (25)
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Figure 6.44: 13C NMR (101 MHz, Chloroform-d) (25)

Figure 6.45: 1H NMR (400 MHz, Chloroform-d) (26)
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Figure 6.46: 13C NMR (101 MHz, Chloroform-d) (26)

Figure 6.47: 1H NMR (400 MHz, Chloroform-d) (27)
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Figure 6.48: 13C NMR (101 MHz, Chloroform-d) (27)

Figure 6.49: 1H NMR (400 MHz, Chloroform-d) (28)
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Figure 6.50: 13C NMR (101 MHz, Chloroform-d) (28)

Figure 6.51: 1H NMR (400 MHz, Chloroform-d) (29)
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Figure 6.52: 13C NMR (101 MHz, Chloroform-d) (29)

Figure 6.53: 1H NMR (400 MHz, Chloroform-d) (30)
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Figure 6.54: 13C NMR (101 MHz, Chloroform-d) (30)

Figure 6.55: 1H NMR (400 MHz, Chloroform-d) (31)
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Figure 6.56: 13C NMR (101 MHz, Chloroform-d) (31)

Figure 6.57: 1H NMR (400 MHz, Chloroform-d) (32)
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Figure 6.58: 13C NMR (101 MHz, Chloroform-d) (32)

Figure 6.59: 1H NMR (400 MHz, Chloroform-d) (33)
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Figure 6.60: 13C NMR (101 MHz, Chloroform-d) (33)

Figure 6.61: 1H NMR (400 MHz, Chloroform-d) (34)
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Figure 6.62: 13C NMR (101 MHz, Chloroform-d) (34)

Figure 6.63: 1H NMR (400 MHz, Chloroform-d) (35)
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Figure 6.64: 13C NMR (101 MHz, Chloroform-d) (35)

Figure 6.65: 1H NMR (400 MHz, Chloroform-d) (36)
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Figure 6.66: 13C NMR (101 MHz, Chloroform-d) (36)

Figure 6.67: 1H NMR (600 MHz, Chloroform-d) (37)
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Figure 6.68: 13C NMR (151 MHz, Chloroform-d) (37)

Figure 6.69: 1H NMR (400 MHz, Chloroform-d) (38)
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Figure 6.70: 13C NMR (101 MHz, Chloroform-d) (38)

Figure 6.71: 1H NMR (400 MHz, Chloroform-d) (39)
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Figure 6.72: 13C NMR (101 MHz, Chloroform-d) (39)

Figure 6.73: 1H NMR (400 MHz, Chloroform-d) (40)
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Figure 6.74: 13C NMR (101 MHz, Chloroform-d) (40)

Figure 6.75: 1H NMR (400 MHz, Chloroform-d) (41)
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Figure 6.76: 13C NMR (101 MHz, Chloroform-d) (41)
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